



(51) International Patent Classification:

*C07H 1/00* (2006.01)      *C12P 19/26* (2006.01)  
*C07H 5/06* (2006.01)      *C12P 19/44* (2006.01)  
*C12P 19/18* (2006.01)

(21) International Application Number:

PCT/IB2013/055181

(22) International Filing Date:

24 June 2013 (24.06.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12173302.6      22 June 2012 (22.06.2012)      EP

(71) Applicant: **GLYCOM A/S** [DK/DK]; Diplomvej 373 Ø,  
1st floor, DK-2800 Kgs. Lyngby (DK).

(72) Inventors: **CHAMPION, Elise**; 9 rue Bégué-David, F-  
31400 Toulouse (FR). **MOLNÁR-GÁBOR, Dóra**; József  
Attila u. 26 3/9, H-1042 Budapest (HU). **DEKANY, Gy-  
ula**; 46 Furness Crescent, Sinnamon Park, Queensland  
4073 (AU).

(74) Agent: **SELDEN, Deborah A.**; Beck Greener, Fulwood  
House, 12 Fulwood Place, London London WC1V 6HR  
(GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,  
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,  
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))

(54) Title: GLYCOSYLATED GALACTOSYL DISACCHARIDES, METHODS FOR THEIR PRODUCTION AND THEIR USE  
IN CONSUMABLE PRODUCTS

(57) Abstract: A method for modifying galactosyl disaccharides in order to enhance their bifidogenic effect, comprising reacting at  
least one glycosyl donor with a precursor galactosyl disaccharide or a mixture of precursor galactosyl disaccharides using enzyme  
catalysis, compounds obtainable by said method and the use of such compounds in consumable products.



WO 2013/190531 A1

**GLYCOSYLATED GALACTOSYL DISACCHARIDES, METHODS FOR THEIR PRODUCTION AND THEIR USE IN CONSUMABLE PRODUCTS****FIELD OF THE INVENTION**

The present invention relates to modified mammalian animal milk, preferably cow or bovine  
5 milk, and a method for making modified oligosaccharides originating from a mammalian  
animal milk, preferably bovine milk oligosaccharides (BMOs).

**BACKGROUND OF THE INVENTION**

It is a well-known fact that human milk is the best dietary source for new-born babies. It  
provides nutrients and energy necessary for babies to thrive and also non-digestible  
10 oligosaccharides (human milk oligosaccharides [HMOs], prebiotics) which promote the  
colonization of microbiota like bifidobacteria and lactobacilli in the small intestine, thus  
establishing gut microflora with many health benefits, such as increased resistance to  
diarrhoea and infections, maturing the immune system and stimulating immune system  
activity.

15 It is also known that the gut microflora of formula-fed infants differs from that of the breast-  
fed infants. In general, the microbiota of breast-fed infants mainly contains bifidobacteria,  
while the microbiota of formula-fed infants is more diverse, with bifidobacteria often being  
the predominant species, but also containing other and less beneficial species in substantial  
amounts. This is presumably due to the lack of non-digestible human milk oligosaccharides in  
20 infant formulae, which act as prebiotics and thus contribute to the bifidogenic microbiota. A  
recent paper has published comparative studies on the bifidogenic index (microbiological and  
biochemical parameters resulting from the growth of bifidobacteria) concerning mother's  
milk and infant formulae without added prebiotics (Martinov et al. *Afr. J. Biotechnol.* **10**,  
2302 (2011)).

25 Recent systematic researches have revealed the oligosaccharide profile of bovine milk and  
compared to that of human milk. Because of the structural similarities, bovine milk has been  
suggested to be the source of functional oligosaccharides to mimic certain beneficial effects of  
human milk oligosaccharides (Tao et al. *J. Dairy Sci.* **91**, 3768 (2008), Zivkovic et al. *Adv.*  
*Nutr.* **2**, 284 (2011), WO 2012/009315 A2).

It has been found that both bifidobacteria and clostridia grow on lactose and cow milk as carbon source, bifidobacteria grows on human milk and human milk oligosaccharides, whereas clostridia are not able to utilize human milk oligosaccharides. Consequently, many clostridia strains do not grow on human milk, presumably due to an inhibition effect  
5 associated with human milk oligosaccharides on the growth of clostridia (Rockova et al. *Anaerobe* **17**, 223 (2011)).

In EP-A-313533, foodstuffs have been provided from ruminant origin, preferably cow milk or milk powder thereof to which has been added lacto-N-tetraose having a beneficial effect on the bacterial flora of the gastro-intestinal tract.

10 WO 2006/087391, WO 2012/160080 and López Leiva et al. *Process Biochem.* **30**, 757 (1995) describe the treatment of cow milk or whey with a  $\beta$ -galactosidase producing an oligosaccharide mixture containing sugar compounds from the milk or whey and galactooligosaccharides.

As HMOs are not available in bulk and ways for their large-scale microbial, enzymatic or  
15 chemical synthesis in a cost-efficient way have not yet been provided, there is still a need for potential bifidogenic oligosaccharide mixtures having prebiotic properties similar to those of HMOs.

## BRIEF DESCRIPTION OF THE INVENTION

The first aspect of the invention is a method for making a mixture of oligosaccharides  
20 originating from a mammalian animal milk, comprising:

- reacting at least one glycosyl donor with a mixture of oligosaccharides originating from a mammalian animal milk under the catalysis of an enzyme capable of transferring said glycosyl moiety, wherein the glycosyl donor is not a galactosyl donor.

25 Advantageously, this method comprises the steps of

- a) providing at least one glycosyl donor,
- b) providing a mixture of oligosaccharides originating from a mammalian animal milk,

- c) providing at least one enzyme comprising a trans-glycosidase and/or a glycosynthase activity;
- d) preparing a mixture of the components provided in steps a), b) and c);
- e) incubating the mixture prepared according to step d);
- 5 f) optionally: repeating steps a), c), d) and e) with the mixture obtained according to step e).

Also advantageously, the glycosyl donor is selected from the group consisting of a sialyl donor, a fucosyl donor, and an optionally galactosylated N-acetyl-glucosaminyl donor.

10 Also advantageously, the sialyl and/or fucosyl and/or optionally galactosylated N-acetyl-glucosaminyl donor has the leaving group selected from fluoro, azido and -OR group, wherein R can be a mono-, di- or oligosaccharide, glycolipid, glycoprotein or glycopeptide, cyclic or acyclic aliphatic group, or aryl residue, or the optionally galactosylated N-acetyl-glucosaminyl donor is an oxazoline.

15 Also advantageously, the mammalian animal is an ungulate and/or ruminant, particularly a domesticated ungulate and/or ruminant, more particularly a cow, goat, sheep, water buffalo or yak, most particularly a cow.

The second aspect of the invention is a mixture of modified oligosaccharides obtainable by the foregoing method.

20 The third aspect of the invention is the use of the foregoing mixture of compounds for enhancing the bifidogenic effect of a consumable product.

The fourth aspect of the invention is a consumable product, advantageously a nutritional formulation, a pharmaceutical formulation or a food supplement, comprising the foregoing mixture of modified oligosaccharides and a nutritionally and/or pharmaceutically acceptable carrier.

25 The fifth aspect of the invention is a preparation of the foregoing consumable product, using the foregoing mixture of modified oligosaccharides.

The sixth aspect of the invention is a method for enhancing the bifidogenic effect of oligosaccharide compounds originating from a mammalian animal milk, comprising:

- reacting at least one glycosyl donor with a mixture of oligosaccharides originating from a mammalian animal milk under the catalysis of an enzyme capable of transferring said glycosyl moiety, wherein the glycosyl donor is not a galactosyl donor.

## 5 DETAILED DESCRIPTION OF THE INVENTION


In the present invention, the term “mammalian animal milk” preferably means the liquid foodstuff produced in the mammary glands of a mammalian animal to feed its young. Preferably, the mammalian animal is an ungulate and/or ruminant, e.g. horse, donkey, deer, cow, goat, sheep, yak, bison, water buffalo, moose, alpaca, camel, llama, etc. More  
10 preferably, the mammalian animal is a domesticated ruminant (cattle) such as a cow, goat, sheep, water buffalo or yak, most preferably a cow. In this regard the “mammalian animal milk” is not human (mother’s) milk.

The structures of 25 oligosaccharides from as much as 39 detected in bovine milk have been elucidated so far (see Urashima et al. *Milk Oligosaccharides*, Chapter VII, Nova Biomedical  
15 Books, NY, 2011; Tao et al. *J. Dairy Sci.* **91**, 3768 (2008); WO 2012/009315 A2). Approximately 65 % of the total oligosaccharides in bovine colostrum are sialylated, of which 3-SL and 6-SL can be also found in human milk. Some acidic oligosaccharides contain N-glycolyl neuraminyl residue. Among neutral oligosaccharides, LNnT and LNnH are common in human milk. No fucose is present in cow milk.


20 Goat milk, compared to bovine milk, has an oligosaccharide profile more similar to that of human milk. The major oligosaccharides from goat milk are 3-SL, 6-SL, disialyl-lactose, N-glycolylneuraminyl-lactose, 3-galactosyl-lactose, LNH and N-acetylglucosaminyl-lactose. No fucose appears to be in goat milk either (Martinez-Ferez et al. *Int. Dairy. J.* **16**, 173 (2006)).

Interestingly, elephant milk resembles human milk the most with regard to the glycom  
25 (oligosaccharide) pattern when compared to milk of other species (Kunz et al. *Br. J. Nutr.* **82**, 391 (1999)).


Herein, the term „fucosyl” preferably means a L-fucopyranosyl group attached to the core oligosaccharide with  $\alpha$ -interglycosidic linkage:




“N-acetyl-glucosaminy” preferably means an N-acetyl-2-amino-2-deoxy-D-glucopyranosyl (GlcNAc) group linked with  $\beta$ -linkage:



- 5 „N-acetyl-lactosaminy” preferably means the glycosyl residue of N-acetyl-lactosamine (LacNAc, Gal $\beta$ 1-4GlcNAc) linked with  $\beta$ -linkage:




Furthermore, the term „lacto-N-biosyl” preferably means the glycosyl residue of lacto-N-biose (LNB, Gal $\beta$ 1-3GlcNAc) linked with  $\beta$ -linkage:



10

The term „sialyl” preferably means the glycosyl residue of sialic acid (N-acetyl-neuraminic acid, Neu5Ac) linked with  $\alpha$ -linkage:



15

The term “optionally substituted phenoxy” preferably means a phenoxy group optionally substituted with 1 or 2 groups selected from nitro, halogen, alkyl, hydroxyalkyl, amino, formyl, carboxyl and alkoxy carbonyl, or two substituents in ortho position can form a methylenedioxy-group. Preferred substituents are nitro (preferably in 2- and/or 4-position), halogen (preferably fluoro and chloro). Especially preferred substituted phenoxy groups are selected from 4-nitrophenoxy, 2,4-dinitrophenoxy, 2-chloro-4-nitrophenoxy, 2-fluoro-4-

nitrophenoxy, 3-fluoro-4-nitrophenoxy, 2-hydroxymethyl-4-nitrophenoxy, 3-hydroxymethyl-4-nitrophenoxy, 2-formyl-4-nitrophenoxy, 2-carboxy-4-nitrophenoxy, 2-methoxycarbonyl-4-nitrophenoxy, 5-fluoro-2-nitrophenoxy, 4-methoxycarbonyl-2-nitrophenoxy, 4-carboxy-2-nitrophenoxy, 2-aminophenoxy and 3,4-methylenedioxy-phenoxy.

- 5 The term “optionally substituted pyridinyloxy” preferably means a pyridinyloxy, more preferably 2- or 4-pyridinyloxy group, optionally substituted with 1 or 2 groups selected from nitro, halogen, alkyl and alkoxy. Especially preferred pyridinyloxy groups are selected from 4-pyridinyloxy, 2-pyridinyloxy, 3-nitro-2-pyridinyloxy and 3-methoxy-2-pyridinyloxy.

Herein, the term “donor” is preferably to be understood as a compound that provides or  
10 transfers a specific moiety in a chemical reaction, e.g. a nucleophilic or electrophilic substitution reaction, to a further compound, preferably an acceptor. Particularly preferably, a “donor” is understood as a compound that provides or transfers a glycosyl residue to a further compound, preferably an acceptor, wherein the donor is not restricted to naturally occurring donors.

- 15 Likewise, the term “acceptor” is preferably to be understood as a compound that receives a specific moiety, preferably a glycosyl moiety, in a chemical reaction, e.g. nucleophilic or electrophilic substitution reaction, from a further compound, preferably a donor as defined above.


According to the first aspect of the invention, the present invention provides a method for  
20 making a mixture of oligosaccharides originating from a mammalian animal milk, the method comprising reacting at least one glycosyl donor with a mixture of oligosaccharides originating from a mammalian animal milk under the catalysis of an enzyme capable of transferring said glycosyl moiety, provided that the glycosyl donor is not a galactosyl donor.

According to a preferred embodiment of the first aspect, the method comprises the steps of:

- 25 a) providing at least one glycosyl donor,  
b) providing oligosaccharides originating from a mammalian animal milk,  
c) providing at least one enzyme comprising a trans-glycosidase and/or a glycosynthase activity;


- d) preparing a mixture of the components provided in steps a), b) and c);
- e) incubating the mixture prepared according to step d);
- f) optionally: repeating steps a), c), d) and e) with the mixture obtained according to step e).

5 According to step a) at least one glycosyl donor is provided, and the glycosyl donor is not a galactosyl donor. Compounds for use as glycosyl donors in step a) can preferably be selected from the group consisting of: a sialyl donor, a fucosyl donor and an optionally galactosylated N-acetyl-glucosaminyl donor. More preferably, said sialyl donor, fucosyl donor and/or optionally galactosylated N-acetyl-glucosaminyl donor has a leaving group selected from the group consisting of: fluoro, azido and -OR group, wherein R can be a mono-, di- or  
 10 oligosaccharide, glycolipid, glycoprotein or glycopeptide, cyclic or acyclic aliphatic group, or aryl residue; or wherein the optionally galactosylated N-acetyl-glucosaminyl donor is an oxazoline. Even more preferably said sialyl donor is characterized by formula **1**, said fucosyl donor is characterized by formula **2** and said optionally galactosylated N-acetyl-glucosaminyl donor is characterized by formulae **3** or **4**  
 15 donor is characterized by formulae **3** or **4**



wherein X, independently, is selected from the group consisting of azide, fluoro, optionally substituted phenoxy, optionally substituted pyridinyloxy, lactose moiety, group A, group B, group C and group D






wherein  $R_a$  is independently H or alkyl, or two vicinal  $R_a$  groups represent a  $=C(R_b)_2$  group, wherein  $R_b$  is independently H or alkyl,  $R_c$  is independently selected from the group consisting of alkoxy, amino, alkylamino and dialkylamino,  $R_d$  is selected from the group consisting of H, alkyl and  $-C(=O)R_e$ , wherein  $R_e$  is OH, alkoxy, amino, alkylamino, dialkylamino, hydrazino, alkylhydrazino, dialkylhydrazino or trialkylhydrazino;

and  $R_1$  and  $R_2$ , independently, is H or  $\beta$ -D-galactopyranosyl group with the proviso that at least one of the  $R_1$  and  $R_2$  groups is H.

The donors are preferably selected with reference to the enzymes used during the method of the present invention. Preferably, the donors are selected depending on the enzyme's transglycosidase activity from compounds according to formulae 1 to 3, wherein X is optionally substituted 4-nitrophenoxy, lactose moiety, group A, group B, group C, or from compounds of formula 4. Likewise preferably, the donors are selected depending on the enzyme's glycosynthase activity from compounds according to formulae 1 to 3, wherein X is azide or fluoro. Both selections can be carried out independently of each other or together.

Furthermore, compounds for use as donors in step a) can preferably be selected from compounds according to formulae 1 to 3, wherein X is lactose moiety, 4-nitrophenoxy, 2,4-dinitrophenoxy, 2-chloro-4-nitrophenoxy, 2,5-dimethyl-3-oxo-(2H)-furan-4-yloxy, 2-ethyl-5-methyl-3-oxo-(2H)-furan-4-yloxy, 5-ethyl-2-methyl-3-oxo-(2H)-furan-4-yloxy, 4,6-dimethoxy-1,3,5-triazin-2-yloxy, 4,6-diethoxy-1,3,5-triazin-2-yloxy, 4-methylumbelliferyloxy, or from compounds of formula 4 represented by formulae 5, 6 or 7.



More preferably, the donor used in step a) is 2'-FL, 3'-SL and/or 6'-SL. Alternatively, if one of these compounds is intended to be used as a donor can be found in the mammalian animal milk to be modified, then it is not necessary to add it externally.

In step c) at least one enzyme comprising a transglycosidase activity and/or a glycosynthase activity is provided.

Enzymes suitable in step c) typically comprise at least one enzyme comprising a transglycosidase activity and/or a glycosynthase activity, preferably selected from enzymes having, e.g. a fucosidase, trans-fucosidase or fucosynthase activity, a sialidase (neuraminidase) or trans-sialidase (transneuraminidase) activity, a N-acetylglucosaminidase or trans-N-acetylglucosaminidase activity, a lacto-N-biosidase or trans-lacto-N-biosidase activity and/or a N-acetyllactosaminidase or trans-N-acetyllactosaminidase activity, or any further enzyme having such an activity. Even more preferably, enzymes suitable in step c) can be selected from the group comprising wild type or mutated glycosidases or transglycosidases, preferably wild type or mutated glycosidases or transglycosidases having a fucosidase, trans-fucosidase or fucosynthase activity, a sialidase (neuraminidase) or trans-sialidase (transneuraminidase) activity, a N-acetylglucosaminidase or trans-N-acetylglucosaminidase activity, a lacto-N-biosidase or trans-lacto-N-biosidase activity and/or a N-acetyllactosaminidase or trans-N-acetyllactosaminidase activity, or preferably having  $\alpha$ -trans-fucosidase,  $\alpha$ -trans-sialidase,  $\beta$ -trans-N-acetylglucosaminidase,  $\beta$ -trans-lacto-N-biosidase and/or  $\beta$ -trans-N-acetyllactosaminidase activity.

The source of the enzymes suitable in step c) furthermore can be selected from any genus known to a skilled person to express or secrete at least one enzyme as defined above, e.g. an enzyme having a transglycosidase activity and/or a glycosynthase activity, preferably an enzyme having a fucosidase, trans-fucosidase or fucosynthase activity, a sialidase (neuraminidase) or trans-sialidase (transneuraminidase) activity, a N-acetylglucosaminidase or trans-N-acetylglucosaminidase activity, a lacto-N-biosidase or trans-lacto-N-biosidase activity and/or a N-acetyllactosaminidase or trans-N-acetyllactosaminidase activity, or preferably having  $\alpha$ -trans-fucosidase,  $\alpha$ -trans-sialidase,  $\beta$ -trans-N-acetylglucosaminidase,  $\beta$ -trans-lacto-N-biosidase and/or  $\beta$ -trans-N-acetyllactosaminidase activity, or any further enzyme having such an activity. Even more preferably, the source of the enzymes suitable in

step c) can be selected from non-pathogenic bacteria selected from *Bacillus*, *Bifidobacterium*, *Lactobacillus*, *Leuconostoc*, *Lactococcus*, *Streptococcus*, *Streptomyces*, *Sulfolobus*, *Thermotoga*, or *Trypanosoma*.

Even more preferably, the source of enzymes suitable in step c) are selected from the group comprising the non-pathogenic bacteria *Bacillus circulans*, lactic acid bacteria, such as *Bifidobacterium bifidum* JCM 1254, *Bifidobacterium bifidum* NCIMB 41171, *Bifidobacterium bifidum* NCIMB 41171, *Bifidobacterium bifidum* JCM1254, *Bifidobacterium bifidum* JCM1254, *Bifidobacterium bifidum* PRL2010, *Bifidobacterium bifidum* PRL2010, *Bifidobacterium bifidum* S17, *Bifidobacterium bifidum* S17, *Bifidobacterium dentium* Bd1, *Bifidobacterium longum* subsp. *infantis* ATCC 15697, *Bifidobacterium longum* subsp. *longum* JDM 301, *Bifidobacterium longum* subsp. *infantis* JCM 1222, *Lactobacillus casei* BL23, *Streptomyces* sp., *Sulfolobus solfataricus* P2, *Thermotoga maritima* MSB8, and *Trypanosoma cruzi*.

Particularly preferred microorganisms in the above context, particularly for targeted glycosidases / transglycosidases / glycosynthases, comprise lactic acid bacteria. Lactic acid bacteria, and more particularly non-pathogenic bacteria from the genus *Bifidobacterium* contain a series of glycosidases including  $\alpha$ -2,3/6 sialidases (GH33),  $\alpha$ -1,2/3/4 fucosidases (GH29 and GH95), lacto-N-biosidases (GH20),  $\beta$ -galactosidases (GH2) and  $\beta$ -N-acetylhexosaminidases (GH18, GH20, GH56, GH84, GH85 and GH123) that are able to recognize prebiotics and/or milk oligosaccharides. Depending on the bifidobacteria strains, these glycosidases are intra- or extracellular enzymes.

A further aspect regarding the use of glycosidases and/or glycosynthases from lactic acid bacteria concerns the industrial importance of such bacteria since they have the GRAS (generally recognized as safe) status. According to another more preferred aspect the glycosidase and/or glycosynthases displaying a trans-fucosidase, trans-sialidase, trans-N-acetylglucosaminidase, trans-lacto-N-biosidase and/or trans-N-acetyllactosaminidase activity, preferably a  $\alpha$ -trans-fucosidase,  $\alpha$ -trans-sialidase,  $\beta$ -trans-N-acetylglucosaminidase,  $\beta$ -trans-lacto-N-biosidase and/or  $\beta$ -trans-N-acetyllactosaminidase activity, is a wild type or an engineered glycosidase, and most preferably a wild type glycosidase is obtained from the group consisting of lactic acid bacteria, wherein the glycosidase is converted to a

transglycosidase by rational engineering or/and directed evolution. A glycosidase and/or glycosynthase obtained from the group consisting of lactic acid bacteria is most preferably a glycosidase from *Bifidobacterium*, *Lactobacillus*, *Lactococcus*, *Streptococcus* or *Leuconostoc*. A glycosidase selected from the genus *Bifidobacterium* is most preferably a glycosidase from *Bifidobacterium longum subsp. Infantis*, *Bifidobacterium longum subsp. Longum*, *Bifidobacterium breve*, *Bifidobacterium bifidum* and *Bifidobacterium catenulatum*.

Furthermore, engineered fucosidases from thermophilic organisms such as *Sulfolobus solfataricus* and *Thermotoga maritima* have recently been developed, which can be used in the method of the present invention. These thermostable glycosidases have considerable potential for industrial inventions since they can be used in biotechnological processes at elevated temperatures, so facilitating the process, preventing risk of contamination, and increasing the solubility of the compounds used in the reaction.

According to another more preferred embodiment, the glycosidase and/or glycosynthase enzyme displaying a trans-fucosidase, trans-sialidase, trans-N-acetylglucosaminidase, trans-lacto-N-biosidase and/or trans-N-acetyllactosaminidase activity, preferably an  $\alpha$ -trans-fucosidase,  $\alpha$ -trans-sialidase,  $\beta$ -trans-N-acetylglucosaminidase,  $\beta$ -trans-lacto-N-biosidase and/or  $\beta$ -trans-N-acetyllactosaminidase activity, is a wild type or an engineered glycosidase. Most preferably, the wild type glycosidase is obtained from the group consisting of thermophilic organisms, which glycosidase is converted to a transglycosidase by rational engineering or/and directed evolution. An  $\alpha$ -L-fucosidase obtained from thermophilic organisms is most preferably an  $\alpha$ -L-fucosidase from *Thermotoga maritima* and *Sulfolobus solfataricus*.

Preferably, the at least one enzyme comprising a transglycosidase activity and/or a glycosynthase activity can be selected from an enzyme exhibiting a fucosidase, trans-fucosidase or fucosynthase activity, preferably as described below. In this context, enzymes having a fucosidase, trans-fucosidase or fucosynthase activity, more preferably an  $\alpha$ -trans-fucosidase activity, are preferably selected from fucosidases in general, and more preferably from  $\alpha$ -L-fucosidases, e.g.  $\alpha$ -L-fucosidases as classified according to EC 3.2.1.38 and 3.2.1.51.  $\alpha$ -L-Fucosidases are widely spread in living organisms such as mammals, plants, fungi and bacteria. These enzymes belong to the families 29 and 95 of the glycoside

hydrolases (GH29 and GH95) as defined by the CAZY nomenclature (<http://www.cazy.org>). Fucosidases from GH29 are retaining enzymes (3D structure:  $(\beta/\alpha)_8$ ) whereas fucosidases from GH95 are inverting enzymes (3D structure:  $(\alpha/\alpha)_6$ ). The substrate specificity of the GH29 family is broad whereas that of the GH95 family is strict to  $\alpha$ 1,2-linked fucosyl

5 residues. The GH29 family seems to be divided into two subfamilies. One subfamily typically has strict specificity towards  $\alpha$ 1,3- and  $\alpha$ 1,4-fucosidic linkages. The members of a further subfamily have broader specificity, covering all  $\alpha$ -fucosyl linkages.  $\alpha$ -L-fucosidases generally hydrolyse the terminal fucosyl residue from glycans. These enzymes are also capable of acting as catalysts for fucosylation reactions due to their transfucosylation activity and thus  
10 can be used in the context of the method of the present invention, preferably under kinetically controlled conditions.

Fucosidases, which can be employed in the context of the present invention, can also comprise engineered fucosidases. Such engineered fucosidases preferably comprise engineered  $\alpha$ -L-fucosidases, preferably engineered fucosidases derived from fucosidases as  
15 described above, e.g. an engineered  $\alpha$ -1,2-L-fucosynthase from *Bifidobacterium bifidum*,  $\alpha$ -L-fucosynthases from *Sulfolobus solfataricus* and *Thermotoga maritima*, etc. Such engineered fucosidases show an acceptor dependent regioselectivity and are devoid of product hydrolysis activity. Furthermore, engineered fucosidases preferably comprise  $\alpha$ -L-fucosidase from *Thermotoga maritima*, which has also been recently converted into an efficient  $\alpha$ -L-trans-  
20 fucosidase by directed evolution (see Osanjo et al. *Biochemistry* **46**, 1022 (2007)).

Even more preferably, the at least one enzyme having a fucosidase and/or trans-fucosidase and/or fucosynthase activity can be selected from  $\alpha$ -L-fucosidases derived from *Thermotoga maritima* MSB8, *Sulfolobus solfataricus* P2, *Bifidobacterium bifidum* JCM 1254, *Bifidobacterium bifidum* JCM 1254, *Bifidobacterium longum subsp. infantis* ATCC 15697,  
25 *Bifidobacterium longum subsp. infantis* ATCC 15697, *Bifidobacterium longum subsp. infantis* JCM 1222, *Bifidobacterium bifidum* PRL2010, *Bifidobacterium bifidum* S17, *Bifidobacterium longum subsp. longum* JDM 301, *Bifidobacterium dentium* Bd1, or *Lactobacillus casei* BL23, etc.

Even more preferably, the at least one enzyme having a fucosidase and/or trans-fucosidase  
30 and/or fucosynthase activity can be selected from following  $\alpha$ -L-fucosidases as defined

- according to the following deposit numbers gi|4980806 (*Thermotoga maritima* MSB8),  
 gi|13816464 (*Sulfolobus solfataricus*), gi|34451973 (*Bifidobacterium bifidum* JCM 1254),  
 gi|242345155 (*Bifidobacterium bifidum*), gi|213524647 (*Bifidobacterium longum subsp.*  
*infantis*), gi|213522629 (*Bifidobacterium longum subsp. infantis* ATCC 15697), gi|213522799  
 5 (*Bifidobacterium longum subsp. infantis* ATCC 15697), gi|213524646 (*Bifidobacterium*  
*longum subsp. infantis* ATCC 15697), gi|320457227 (*Bifidobacterium longum subsp. infantis*  
 JCM 1222), gi|320457408 (*Bifidobacterium longum subsp. infantis* JCM 1222), gi|320459369  
 (*Bifidobacterium longum subsp. infantis* JCM 1222), gi|320459368 (*Bifidobacterium longum*  
*subsp. infantis* JCM 1222), gi|310867039 (*Bifidobacterium bifidum* PRL2010), gi|310865953  
 10 (*Bifidobacterium bifidum* PRL2010), gi|309250672 (*Bifidobacterium bifidum* S17),  
 gi|309251774 (*Bifidobacterium bifidum* S17), gi|296182927 (*Bifidobacterium longum subsp*  
*longum* JDM 301), gi|296182928 (*Bifidobacterium longum subsp longum* JDM 301),  
 gi|283103603 (*Bifidobacterium dentium* Bd1), gi|190713109 (*Lactobacillus casei* BL23),  
 gi|190713871 (*Lactobacillus casei* BL23), gi|190713978 (*Lactobacillus casei* BL23), etc., or a  
 15 sequence exhibiting a sequence identity with one of the above mentioned enzyme sequences  
 having a fucosidase and/or trans-fucosidase activity of at least 70 %, more preferably at least  
 80 %, more preferably at least 85 %, even more preferably at least 90 % and most preferably  
 at least 95 % or even 97 %, 98 % or 99 % as compared to the entire wild type sequence on  
 amino acid level.
- 20 Wild type or engineered fucosidases as defined above, displaying transfucosidase activity and  
 showing a  $\alpha$ 1-2,  $\alpha$ 1-3 and/or  $\alpha$ 1-4 regioselectivity, can be used in the present invention. Such  
 wild type or engineered fucosidases preferably display transfucosidase activity and catalyse  
 the transfer of the fucosyl residue to:
- the galactose of the lacto-N-biosyl group with 1-2 interglycosidic linkage and/or
  - 25 - the N-acetyl-glucosamine of the lacto-N-biosyl group with 1-4 interglycosidic linkage  
 and/or
  - the N-acetyl-glucosamine of the N-acetyl-lactosaminyl group with 1-3 interglycosidic  
 linkage and/or

- a galactosyl moiety of the mammalian animal milk oligosaccharide chain, preferably to a terminal galactosyl moiety of that chain, with 1-2 or 1-3 interglycosidic linkage and/or
  - a N-acetylglucosaminyl moiety, preferably to a terminal N-acetylglucosaminyl moiety with 1-3 or 1-4 interglycosidic linkage and/or
- 5     - a N-acetylgalactosaminyl moiety, preferably to a terminal N-acetylgalactosaminyl moiety with 1-3 interglycosidic linkage.

Also preferably, the regioselectivity the  $\alpha$ -L-fucosidases with fucosidase/trans-fucosidase/fucosynthase activity used in the method of this invention matches the fucosyl donor of formula 2 provided in step a) when X means a lactose moiety. In this regard, when

10     2'-FL is added in step a), then a  $\alpha$ 1-2-L-fucosidase with fucosidase/trans-fucosidase/fucosynthase activity is preferably provided in step c), and when 3-FL is added in step a), then a  $\alpha$ 1-3-L-fucosidase with fucosidase/trans-fucosidase/fucosynthase activity is preferably provided in step c).

- 15     Particularly preferred  $\alpha$ -L-fucosidases or the wild types of engineered fucosidases with fucosidase/trans-fucosidase/fucosynthase activity are listed in the following Table 1:

GI number in GenBank Database	Organisms
gi 4980806	<i>Thermotoga maritima</i> MSB8
gi 13816464	<i>Sulfolobus solfataricus</i> P2
gi 34451973	<i>Bifidobacterium bifidum</i> JCM 1254
gi 242345155	<i>Bifidobacterium bifidum</i> JCM 1254
gi 213524647	<i>Bifidobacterium longum subsp. infantis</i> ATCC 15697
gi 213522629	<i>Bifidobacterium longum subsp. infantis</i> ATCC 15697
gi 213522799	<i>Bifidobacterium longum subsp. infantis</i> ATCC 15697
gi 213524646	<i>Bifidobacterium longum subsp. Infantis</i> ATCC 15697
gi 320457227	<i>Bifidobacterium longum subsp. infantis</i> JCM 1222
gi 320457408	<i>Bifidobacterium longum subsp. infantis</i> JCM 1222
gi 320459369	<i>Bifidobacterium longum subsp. infantis</i> JCM 1222
gi 320459368	<i>Bifidobacterium longum subsp. infantis</i> JCM 1222
gi 310867039	<i>Bifidobacterium bifidum</i> PRL2010
gi 310865953	<i>Bifidobacterium bifidum</i> PRL2010
gi 309250672	<i>Bifidobacterium bifidum</i> S17

gi 309251774	<i>Bifidobacterium bifidum</i> S17
gi 296182927	<i>Bifidobacterium longum subsp longum</i> JDM 301
gi 296182928	<i>Bifidobacterium longum subsp longum</i> JDM 301
gi 283103603	<i>Bifidobacterium dentium</i> Bd1
gi 190713109	<i>Lactobacillus casei</i> BL23
gi 190713871	<i>Lactobacillus casei</i> BL23
gi 190713978	<i>Lactobacillus casei</i> BL23

**Table 1:** Preferred  $\alpha$ -L-fucosidases

Likewise preferably, the at least one enzyme comprising a transglycosidase activity and/or a glycosynthase activity can be selected from an enzyme exhibiting a sialidase or trans-sialidase activity, preferably as described in the following. In this context, enzymes having a sialidase or trans-sialidase activity are preferably selected from a sialidase or trans-sialidase as described in the following, e.g. sialidases (EC 3.2.1.18) and trans-sialidases (EC 2.4.1.-) as classified according to the the GH33 family. They are retaining enzymes. Sialidases and trans-sialidases are widely distributed in nature. They are found particularly in diverse virus families and bacteria, and also in protozoa, some invertebrates and mammals. These enzymes differ in their biochemical properties, e.g., kinetics, binding affinity or substrate preference. Nevertheless, they possess conserved domains and structural similarities. Trans-sialidases differ from sialidases since they can transfer sialic acids, preferably  $\alpha$ -2,3-bonded sialic acids, from a donor molecule to an acceptor derivative, which is preferably a terminal galactose moiety with a  $\beta$ -interglycosidic linkage. As a result of this transfer, an  $\alpha$ -glycosidic bond is formed between the sialic acid and the acceptor. However, if there is no suitable acceptor, the trans-sialidase hydrolyses the sialic acid.

The first trans-sialidase enzyme described was found in *Trypanosoma cruzi*, a protozoa which causes Chagas disease. This trans-sialidase (TcTS) has been extensively studied. Since that time trans-sialidases have been detected in several other trypanosome types such as *Trypanosoma brucei gambiense*, *Trypanosoma brucei rhodesiense*, *Trypanosoma brucei brucei* and *Trypanosoma congolense*. Moreover, the existence of trans-sialidases has been shown in *Endotrypanum* types, in *Corynebacterium diphtheriae* and even in human plasma.

Sialidases can be classified into two different subgroups, endo- and exo-sialidases. The endo-sialidases hydrolyse sialic acid linkages internal to macromolecules, while the exo-sialidases attack terminal sialic acid linkages, and desialylate glycoproteins, glycopeptides,



gangliosides, oligosaccharides and polysaccharides. Recently, sialidases from *Bifidobacterium bifidum* and *Bifidobacterium longum subsp. infantis* have been identified, cloned and characterized. These sialidases can cleave and so recognize both  $\alpha$ -2,3- and  $\alpha$ -2,6-linked sialosides. Sialidases from *Bifidobacterium longum subsp. infantis* have a consistent preference for  $\alpha$ -2,6-linkage whereas sialidases from *Bifidobacterium bifidum* have a consistent preference for  $\alpha$ -2,3-linkage. These enzymes are also capable of acting as catalysts for sialylation reactions due to their trans-sialidase activity and thus can be used in the context of the method of the present invention, preferably under kinetically controlled conditions.

Sialidases, which can be employed in the context of the present invention, can also comprise engineered sialidases. Based on sequence and structure comparisons, sialidase from *Trypanosoma rangeli* can be mutated at six positions, wherein the resulting mutant is able to display a significant level of trans-sialidase activity (see Paris et al. *J. Mol. Biol.* **345**, 923 (2005)). On the other hand, truncation of a sialyl transferase from *Photobacterium damsela* resulted in an enzyme having  $\alpha$ 2-6-trans-sialidase activity (Cheng et al. *Glycobiology* **20**, 260 (2010)).

Even more preferably, the at least one enzyme having a sialidase and/or trans-sialidase activity can be selected from sialidases or trans-sialidases derived from *Bifidobacterium longum subsp. infantis* ATCC 15697, *Bifidobacterium bifidum* JCM1254, *Bifidobacterium bifidum* S17, *Bifidobacterium bifidum* PRL2010, *Bifidobacterium bifidum* NCIMB 41171, *Trypanosoma cruzi*, etc.

Even more preferably the at least one enzyme having a sialidase and/or trans-sialidase activity can be selected from sialidases or trans-sialidases as defined according to the following deposit numbers: gi|213524659 (*Bifidobacterium longum subsp. infantis* ATCC 15697), gi|213523006 (*Bifidobacterium longum subsp. infantis* ATCC 15697), siab2 (*Bifidobacterium bifidum* JCM1254), further sialidases or trans-sialidases from *Bifidobacterium bifidum* JCM1254), gi|309252191 (*Bifidobacterium bifidum* S17), gi|309252190 (*Bifidobacterium bifidum* S17), gi|310867437 (*Bifidobacterium bifidum* PRL2010), gi|310867438 (*Bifidobacterium bifidum* PRL2010), gi|224283484 (*Bifidobacterium bifidum* NCIMB 41171), gi|313140638 (*Bifidobacterium bifidum* NCIMB 41171), gi|47252690 (*Trypanosoma cruzi*), gi|432485 (*Trypanosoma cruzi*), gi|343957998 (*Trypanosoma congolense*), gi|343958004

(*Trypanosoma congolense*) , gi|2988379 (*Photobacterium damsela*) etc., or a sequence exhibiting a sequence identity with one of the above mentioned enzyme sequences having a sialidase and/or trans-sialidase activity of at least 70 %, more preferably at least 80 %, more preferably at least 85 %, even more preferably at least 90 % and most preferably at least 95 %  
 5 or even 97 %, 98 % or 99 % as compared to the entire wild type sequence on amino acid level.

Additionally, wild type or engineered sialidases as defined above can be utilized herein, which display trans-sialidase activity and show a  $\alpha$ ,2-3 and/or  $\alpha$ ,2-6 and/or  $\alpha$ 2-8 regioselectivity. Such linkages are preferably targeted in the present invention. Such wild type  
 10 or engineered sialidases preferably display trans-sialidase activity and catalyse the transfer of the sialyl residue to:

- the galactose of the lacto-N-biosyl group with 2-3 interglycosidic linkage and/or
- the N-acetyl-glucosamine of the lacto-N-biosyl group with 2-6 interglycosidic linkage and/or
- 15 - the galactose of the N-acetyl-lactosaminyl group with 2-6 interglycosidic linkage and/or
- a galactosyl moiety of the mammalian animal milk oligosaccharide chain, preferably to a terminal galactosyl moiety of that chain with 2-3 or 2-6 interglycosidic linkage,
- a N-acetylglucosaminyl moiety, preferably to a terminal N-acetylglucosaminyl moiety with 2-3 or 2-6 interglycosidic linkage,
- 20 - a N-acetylgalactosaminyl moiety, preferably to a terminal N-acetylgalactosaminyl moiety with 2-3 or 2-6 interglycosidic linkage,
- a sialyl moiety with 2-8 interglycosidic linkage.

Also preferably, the regioselectivity of the  $\alpha$ -sialidases with sialidase/trans-sialidase activity used in the method of this invention matches the sialyl donor of formula **1** provided in step a)  
 25 when X means a lactose moiety. In this regard, when 3'-SL is added in step a), then a  $\alpha$ 2-3-(trans)sialidase is preferably provided in step c), and when 6'-SL is added in step a), then a  $\alpha$ 2-6-(trans)sialidase is preferably provided in step c).

Particularly preferred sialidases or the wild types of engineered/truncated sialidases with sialidase/trans-sialidase activity are listed in the following Table 2:

GI number in GenBank Database	Organisms
gi 213524659	<i>Bifidobacterium longum subsp. infantis</i> ATCC 15697
gi 213523006	<i>Bifidobacterium longum subsp. infantis</i> ATCC 15697
gi 309252191	<i>Bifidobacterium bifidum</i> S17
gi 309252190	<i>Bifidobacterium bifidum</i> S17
gi 310867437	<i>Bifidobacterium bifidum</i> PRL2010
gi 310867438	<i>Bifidobacterium bifidum</i> PRL2010
gi 224283484	<i>Bifidobacterium bifidum</i> NCIMB 41171
gi 313140638	<i>Bifidobacterium bifidum</i> NCIMB 41171
gi 47252690	<i>Trypanosoma cruzi</i>
gi 432485	<i>Trypanosoma cruzi</i>
gi 343957998	<i>Trypanosoma congolense</i>
gi 343958004	<i>Trypanosoma congolense</i>
gi 2988379	<i>Photobacterium damsela</i>

**Table 2:** Preferred sialidases/trans-sialidases

Additionally, the at least one enzyme comprising a transglycosidase activity and/or a glycosynthase activity can be preferably selected from an enzyme exhibiting a lacto-N-biosidase or trans-lacto-N-biosidase activity, preferably as described in the following. In this context, enzymes having a lacto-N-biosidase or trans-lacto-N-biosidase activity are preferably selected from a lacto-N-biosidase or trans-lacto-N-biosidase as described in the following, e.g. lacto-N-biosidases (EC 3.2.1.140) as classified according to the GH20 family. Lacto-N-biosidases typically proceed through a retaining mechanism. Only two lacto-N-biosidases from *Streptomyces* and *Bifidobacterium bifidum* have been described and characterized up to now, which can be utilized in the present invention as a lacto-N-biosidase or trans-lacto-N-biosidase (see Sano et al. *Proc. Natl. Acad. Sci. USA* **89**, 8512 (1992); Sano et al. *J. Biol. Chem.* **268**, 18560 (1993); Wada et al. *Appl. Environ. Microbiol.* **74**, 3996 (2008)). Lacto-N-biosidases specifically hydrolyse the terminal lacto-N-biosyl residue ( $\beta$ -D-Gal-(1 $\rightarrow$ 3)-D-GlcNAc) from the non-reducing end of oligosaccharides with the structure  $\beta$ -D-Gal-(1 $\rightarrow$ 3)- $\beta$ -D-GlcNAc-(1 $\rightarrow$ 3)- $\beta$ -D-Gal-(1 $\rightarrow$ R). Wada et al. (supra) and Murata et al. (*Glycoconj. J.* **16**, 189 (1999)) also demonstrated the ability of the lacto-N-biosidase from *Bifidobacterium bifidum* and *Aureobacterium* sp. L-101, respectively, to catalyse the transglycosylation by

incubating donor substrates (such as lacto-*N*-tetraose and *p*NP- $\beta$ -LNB) with acceptors (such as various 1-alkanols and lactose).

Even more preferably, the at least one enzyme having a lacto-*N*-biosidase or trans-lacto-*N*-biosidase activity can be selected from lacto-*N*-biosidases or trans-lacto-*N*-biosidases derived from *Bifidobacterium bifidum* JCM1254, *Bifidobacterium bifidum* PRL2010, *Bifidobacterium bifidum* NCIMB 41171, *Aureobacterium* sp. L-101 or *Streptomyces* sp., etc.

Even more preferably the at least one enzyme having a lacto-*N*-biosidase or trans-lacto-*N*-biosidase activity can be selected from lacto-*N*-biosidases or trans-lacto-*N*-biosidases as defined according to the following deposit numbers: gi|167369738 (*Bifidobacterium bifidum*), gi|4096812 (*Streptomyces* sp.), gi|310867103 (*Bifidobacterium bifidum* PRL2010), gi|313140985 (*Bifidobacterium bifidum* NCIMB 41171), etc., or a sequence exhibiting a sequence identity with one of the above mentioned enzyme sequences having a lacto-*N*-biosidase or trans-lacto-*N*-biosidase activity of at least 70 %, more preferably at least 80 %, more preferably at least 85 %, even more preferably at least 90 % and most preferably at least 95 % or even 97 %, 98 % or 99 % as compared to the entire wild type sequence on amino acid level.

Furthermore, wild type or engineered lacto-*N*-biosidases as defined above can be utilized herein, which display trans-lacto-*N*-biosidase activity and show preferably a  $\beta$ 1-3 regioselectivity. Such linkages are preferably targeted in the present invention. Such wild type or engineered lacto-*N*-biosidases preferably display trans-lacto-*N*-biosidase activity and catalyse the transfer of the lacto-*N*-biosyl residue to a galactosyl group with 1-3 interglycosidic linkage are targeted in the present invention.

Particularly preferred lacto-*N*-biosidases with lacto-*N*-biosidase or trans-lacto-*N*-biosidase activity are listed in the following Table 3:

GI number in GenBank Database	Organisms
gi 167369738	<i>Bifidobacterium bifidum</i> JCM1254
gi 4096812	<i>Streptomyces</i> sp.
gi 310867103	<i>Bifidobacterium bifidum</i> PRL2010
gi 313140985	<i>Bifidobacterium bifidum</i> NCIMB 41171

**Table 3:** Preferred lacto-*N*-biosidases or trans-lacto-*N*-biosidases

Furthermore, the at least one enzyme comprising a transglycosidase activity and/or a glycosynthase activity can be preferably selected from an enzyme exhibiting a N-acetyllactosaminidase or trans-N-acetyllactosaminidase activity, preferably as described in the following. In this context, enzymes having a N-acetyllactosaminidase or trans-N-

5 acetyllactosaminidase activity are preferably selected from a N-acetyllactosaminidase or trans-N-acetyllactosaminidase as described in the following, e.g. lacto-N-biosidases (EC 3.2.1.140) as classified according to the GH20 family. Particularly preferably, chitinase from *Bacillus circulans*, more preferably chitinase A1 from *Bacillus Circulans* WL-12 as deposited under gi|142688, can be used as a N-acetyllactosaminidase or trans-N-acetyllactosaminidase,  
 10 or a sequence exhibiting a sequence identity with one of the above mentioned enzyme sequences having a N-acetyllactosaminidase or trans-N-acetyllactosaminidase activity of at least 70 %, more preferably at least 80 %, equally more preferably at least 85 %, even more preferably at least 90 % and most preferably at least 95 % or even 97 %, 98 % or 99 % as compared to the entire wild type sequence on amino acid level. Notably, Shoda et al. showed  
 15 that chitinase A1 from *B. Circulans* WL-12 is able to transfer N-acetyllactosamine with a  $\beta$ -1,6 glycosidic linkage using a 1,2-oxazoline derivative of N-acetyllactosamine (see Shoda et al. *Cellulose* **13**, 477 (2006)).

Additionally, wild type or engineered glycosidases as defined above, which display trans-N-acetyllactosaminidase activity and show a  $\beta$ 1-3 and/or  $\beta$ 1-6 regioselectivity, can be used in  
 20 the present invention. Such wild type or engineered glycosidases preferably display trans-N-acetyllactosaminidase activity and catalyse the transfer of the N-acetyl-lactosaminyl residue to a galactosyl group with 1-3 or 1-6 interglycosidic linkage.

Particularly preferred N-acetyllactosaminidases or trans-N-acetyllactosaminidases are listed in the following Table 4:

GI number in the GenBank Database	Organisms
gi 142688	<i>Bacillus circulans</i>

25 **Table 4:** Preferred N-acetyllactosaminidases or trans-N-acetyllactosaminidases

Furthermore, the at least one enzyme comprising a transglycosidase activity and/or a glycosynthase activity can be preferably selected from an enzyme exhibiting a N-acetylhexosaminidase or trans-N-acetylhexosaminidase activity, preferably as described in the

following. In this context, enzymes having a N-acetylhexosaminidase or trans-N-acetylhexosaminidase activity are preferably selected from a N-acetylhexosaminidase or trans-N-acetylhexosaminidase as described in the following, e.g.  $\beta$ -N-acetylhexosaminidases (systematic name 2-acetamido-2-deoxy- $\beta$ -D-hexopyranoside acetamidodeoxyhexohydrolases, EC 3.2.1.52 (exo-glycosidases) and 3.2.1.96 (endo-glycosidases)) as classified according to the GH3, GH18, GH20, GH56, GH 84, GH85 and GH123 families. Among  $\beta$ -N-acetylhexosaminidases,  $\beta$ -N-acetylglucosaminidases are mainly found in GH3, GH18, GH20, GH84 and GH85 families.

$\beta$ -N-Acetylhexosaminidases have been shown to be universally distributed among most types of living organisms, both prokaryotic and eukaryotic.

In vivo  $\beta$ -N-acetylhexosaminidases catalyse the hydrolysis of glycosidic linkages. When acting as exo-enzymes, they catalyse the cleavage of terminal  $\beta$ -D-GlcNAc and  $\beta$ -D-GalNAc residues in N-acetyl- $\beta$ -D-hexosaminides. In vitro they can catalyse the formation of a new glycosidic bond either by transglycosylation or by reverse hydrolysis (i.e. condensation, see review: Slámová et al., *Biotechnology Advances* **28**, 682 (2010)).

Improved mutants displaying enhanced transglycosylation activity have been described previously. Mutants of endo- $\beta$ -N-acetylglucosaminidase from *Mucor hiemalis* (Endo-M, GH85) as well as mutants of endo-N-acetylglucosaminidase from *Streptococcus pneumoniae* (Endo-D, GH85) exhibit glycosynthase-like activity using sugar oxazoline as a donor substrate (Umekawa et al., *J. Biol. Chem.* **283**, 4469 (2008), Fan et al., *ibid.* **287**, 11272 (2012)).

Additionally, wild type or engineered glycosidases as defined above can be utilized herein, which display trans-N-acetylglucosaminidase activity and show a  $\beta$ 1-3 and/or  $\beta$ 1-6 regioselectivity. Such wild type or engineered glycosidases preferably display trans-N-acetylglucosaminidase activity and catalyse the transfer of the N-acetyl-glucosaminyl residue to a galactosyl group with 1-3 or 1-6 interglycosidic linkage.

Particularly preferred N-acetylglucosaminidases or trans-N-acetylglucosaminidases are listed in the following Table 5, or a sequence exhibiting a sequence identity with one of the below mentioned enzyme sequences having a N-acetylglucosaminidase or trans-N-

acetylglucosaminidase activity of at least 70 %, more preferably at least 80 %, more preferably at least 85 %, even more preferably at least 90 % and most preferably at least 95 % or even 97 %, 98 % or 99 % as compared to the entire wild type sequence on amino acid level.

GI number in GenBank Database	Organisms
gi 16077234	<i>Bacillus subtilis subsp. subtilis str. 168</i>
gi 213522828	<i>Bifidobacterium longum subsp. infantis</i> ATCC 15697
gi 213523089	<i>Bifidobacterium longum subsp. infantis</i> ATCC 15697
gi 213524666	<i>Bifidobacterium longum subsp. infantis</i> ATCC 15697
gi 292673292	<i>Bifidobacterium bifidum</i> JCM 1254
gi 292673294	<i>Bifidobacterium bifidum</i> JCM 1254
gi 4586325	<i>Lactobacillus casei</i> ATCC 27092
gi 10518509	<i>Streptomyces plicatus</i>

5 **Table 5:** Preferred N-acetylglucosaminidases or trans-N-acetylglucosaminidases

As defined above, proteins comprising a transglycosidase and/or a glycosynthase activity as defined above can also comprise engineered proteins comprising a transglycosidase and/or a glycosynthase activity. It is particularly envisaged that wild type or mutated glycosidases displaying a transfucosidase, transsialidase, trans-N-acetylglucosaminidase, trans-lacto-N-biosidase and/or trans-N-acetylglucosaminidase activity, preferably a  $\alpha$ -transfucosidase,  $\alpha$ -transsialidase,  $\beta$ -trans-N-acetylglucosaminidase,  $\beta$ -trans-lacto-N-biosidase and/or  $\beta$ -trans-N-acetylglucosaminidase activity, can be used in the present invention to produce such oligosaccharides. Preparation of such enzymes is preferably carried out via site directed mutagenesis approaches or directed evolution.

15 In rational engineering, novel altered enzymes (mutants) are created via site directed mutagenesis approaches, preferably by introduction of point mutations. This technique generally requires reliance on the static 3D protein structure. The mutations generally affect the active site of the enzymes such that they lose their ability to degrade their transglycosylation products but remain capable of synthesis. A preferred strategy consists of the replacement of the catalytic nucleophile by a non-nucleophilic residue. This modification results in the formation of an inactive mutant or an altered enzyme with reduced transglycosylation activity due the lack of appropriate environment for the formation of the

reactive host-guest complex for transglycosylation. However, in the presence of a more active glycosyl donor (e.g. glycosyl fluoride) that mimics the glycosyl enzyme intermediate, the mutated enzyme is able to transfer efficiently the glycosyl moiety to a suitable acceptor generating a glycoside with inverted anomeric stereochemistry. Such a mutant glycosidase is termed a glycosynthase and their development represents one of the major advances in the use of glycosidases for synthetic purposes. In principle, the glycosynthase concept can be applied to all GH specificities and offer a large panel of enzymes potentially able to synthesize various oligosaccharides with very high yields, up to 95 %.

The second preferred technique is called directed evolution. This strategy comprises random mutagenesis applied to the gene of the selected glycosidase, which thus generates a library of genetically diverse genes expressing glycosidase. Generation of sequence diversity can be performed using well-known methodologies, the most preferable being the error prone polymerase chain reaction (epCR) method. This gene library can be inserted into suitable microorganisms such as *E. coli* or *S. cerevisiae* for producing recombinant variants with slightly altered properties. Clones expressing improved enzymes are then identified with a fast and reliable screening method, selected and brought into a next round of mutation process. The recursive cycles of mutation, recombination and selection are continued as far as mutant(s) with the desired activity and/or specificity is/are evolved. To date, different high-throughput screening methodologies for glycosidases including glycosynthases have been developed. Applying these approaches, effective engineered transglycosidases, including new and more efficient glycosynthases can and have been created and isolated. An  $\alpha$ -L-fucosidase from *Thermotoga maritima* has been recently converted into an efficient  $\alpha$ -L-transfucosidase by directed evolution. The transferase/hydrolysis ratio of the evolved enzyme was 30 times higher than the native enzyme (see Osanjo et al. above).

Proteins comprising a transglycosidase and/or a glycosynthase activity as defined above can also comprise fragments or variants of those protein sequences. Such fragments or variants can typically comprise a sequence having a sequence identity with one of the above mentioned proteins sequences of at least 70 %, more preferably at least 80 %, equally more preferably at least 85 %, even more preferably at least 90 % and most preferably at least 95 %



or even 97 %, 98 % or 99 % as compared to the entire wild type sequence on amino acid level.

“Fragments” of proteins or peptides in the context of the present invention can also comprise a sequence of a protein or peptide as defined herein, which is, with regard to its amino acid sequence N-terminally, C-terminally and/or intrasequentially truncated compared to the amino acid sequence of the original (native) protein. Such truncation can thus occur either on the amino acid level or correspondingly on the nucleic acid level. A sequence identity with respect to such a fragment as defined herein can therefore preferably refer to the entire protein or peptide as defined herein or to the entire (coding) nucleic acid molecule of such a protein or peptide. Likewise, “fragments” of nucleic acids in the context of the present invention can comprise a sequence of a nucleic acid as defined herein, which is, with regard to its nucleic acid molecule 5’-, 3’- and/or intrasequentially truncated compared to the nucleic acid molecule of the original (native) nucleic acid molecule. A sequence identity with respect to such a fragment as defined herein can therefore preferably refer to the entire nucleic acid as defined herein.

“Variants” of proteins or peptides in accordance with this invention (e.g. as encoded by a nucleic acid as defined herein) can be encoded by the nucleic acid molecule of a polymeric carrier cargo complex. Thereby, a protein or peptide can be generated, having an amino acid sequence which differs from the original sequence in one or more mutation(s), such as one or more substituted, inserted and/or deleted amino acid(s). Preferably, these fragments and/or variants have the same biological function or specific activity compared to the full-length native protein, e.g. its specific antigenic property.

“Variants” of proteins or peptides (e.g. as encoded by a nucleic acid as defined herein) can also comprise conservative amino acid substitution(s) compared to their native, i.e. non-mutated physiological, sequence. Those amino acid sequences as well as their encoding nucleotide sequences in particular fall under the term variants as defined herein. Substitutions in which amino acids that originate from the same class are exchanged for one another are called conservative substitutions. In particular, these are amino acids having aliphatic side chains, positively or negatively charged side chains, aromatic groups in the side chains or amino acids having side chains that can enter into hydrogen bridges, e.g. side chains which

have a hydroxyl function. This means that e.g. an amino acid having a polar side chain is replaced by another amino acid having a likewise polar side chain, or, for example, an amino acid characterized by a hydrophobic side chain is substituted by another amino acid having a likewise hydrophobic side chain (e.g. serine (threonine) by threonine (serine) or leucine (isoleucine) by isoleucine (leucine)). Insertions and substitutions are possible, in particular, at those sequence positions which cause no modification to the three-dimensional structure or do not affect the binding region. Modifications to a three-dimensional structure by insertion(s) or deletion(s) can easily be determined e.g. using CD spectra (circular dichroism spectra) (Urry, 1985, Absorption, Circular Dichroism and ORD of Polypeptides, in: Modern Physical  
10 Methods in Biochemistry, Neuberger *et al.* (ed.), Elsevier, Amsterdam).

Furthermore, variants of proteins or peptides as defined herein can also comprise those sequences wherein nucleotides of the nucleic acid are exchanged according to the degeneration of the genetic code, without leading to an alteration of the respective amino acid sequence of the protein or peptide, i.e. the amino acid sequence or at least part thereof can not  
15 differ from the original sequence in one or more mutation(s) within the above meaning.

In order to determine the percentage to which two sequences are identical, e.g. nucleic acid sequences or amino acid sequences as defined herein, preferably the amino acid sequences encoded by a nucleic acid sequence of the polymeric carrier as defined herein or the amino acid sequences themselves, the sequences can be aligned in order to be subsequently  
20 compared to one another. Therefore, e.g. a position of a first sequence can be compared with the corresponding position of the second sequence. If a position in the first sequence is occupied by the same component as is the case at a position in the second sequence, the two sequences are identical at this position. If this is not the case, the sequences differ at this position. If insertions occur in the second sequence in comparison to the first sequence, gaps  
25 can be inserted into the first sequence to allow a further alignment. If deletions occur in the second sequence in comparison to the first sequence, gaps can be inserted into the second sequence to allow a further alignment. The percentage to which two sequences are identical is then a function of the number of identical positions divided by the total number of positions including those positions which are only occupied in one sequence. The percentage to which  
30 two sequences are identical can be determined using a mathematical algorithm. A preferred,

but not limiting, example of a mathematical algorithm which can be used is the algorithm of Karlin et al. *PNAS USA* **90**, 5873 (1993) or Altschul et al. *Nucleic Acids Res.* **25**, 3389 (1997). Such an algorithm is integrated in the BLAST program. Sequences which are identical to the sequences of the present invention to a certain extent can be identified by this program.

5 The proteins as added in step c) can be provided in a free form or alternatively be bound to or immobilized onto a surface. In this specific case, the order of steps a), b) and c) is preferably inverted. Binding to or immobilization onto a surface can be carried out e.g. via electrostatic bonds, van der Waals-bonds, covalent bonds, etc. Binding to or immobilization onto a surface can be furthermore carried out using a covalent linker or a crosslinker, or a Tag, as  
10 known to a skilled person for purification of proteins. Such tags comprise, inter alia, affinity tags or chromatography tags. Affinity tags can include e.g. chitin binding protein (CBP), maltose binding protein (MBP), glutathione-S-transferase (GST), or the Strep-Tag. The poly(His) tag is a widely-used protein tag that binds to metal matrices. Chromatography tags are used to alter chromatographic properties of the protein to afford different resolution across  
15 a particular separation technique, and include e.g. polyanionic amino acids based tags, such as the FLAG-tag. The surface can be the surface of a bioreactor, or any suitable reaction chamber.

According to step d) a mixture is prepared from substances provided by steps a), b) and c). Preferably, such a mixture according to step d) represents a mixture of one, two, three, four,  
20 five, one to five, three to ten, five to ten or even more different donors as defined according to step a), and one, two, three, four, five, two to five, two to ten, two to twenty, five to ten or even more different enzymes comprising transglycosidase activity and/or glycosynthase activity.

In a further step e) the mixture containing at least one compound as defined according to step  
25 a), a mixture of oligosaccharides originated from a mammalian animal milk, preferably BMO, as defined according to step b), and at least one enzyme as added according to step c), together forming a mixture according to step d), are incubated to allow generation of modified products via enzymatic means using the at least one enzyme comprising a transglycosidase activity and/or a glycosynthase activity as defined herein. Such an incubation advantageously  
30 allows the generation of a multiplicity of different modified oligosaccharides, preferably

modified BMO. Generation of such a multiplicity of different modified modified oligosaccharides, preferably modified BMO, is based on the use of enzymes with different activities provided in step c), but also on the use of diverse donors and acceptors according to steps a) and b), preferably as a mixture as already outlined in step d). Utilizing this approach, the method of the present invention advantageously allows variation of the possible number and type of oligosaccharides obtainable by the method in a simple and cost efficient manner. The use of enzymes furthermore allows the preparation of various modified oligosaccharides, preferably modified BMO to be carried out in a stereoselective manner. Generation of modified oligosaccharides, preferably modified BMO, preferably occurs by transferring glycosyl moieties (e.g., a sialyl moiety, fucosyl moiety, N-acetylglucosaminyl moiety, N-acetylglucosaminyl moiety, or lacto-N-biosyl moiety) by forming new bonds at desired positions of the molecule, etc., in a well defined manner to obtain a mixture of various modified oligosaccharides, preferably modified BMO.

Incubation according to step e) preferably occurs with a concentration of (each of the) enzymes in a concentration of 1 mU/l to 1,000 U/l, preferably 10 mU/l to 100 U/l, when the activity capable of forming 1  $\mu$ mol of specific product for a defined protein starting from a defined educt is defined as 1 unit (U), e.g. for a glycotransferase the production of a glycosyl-containing complex carbohydrate at 37 °C in 1 minute. The activity of each enzyme as defined herein can be assessed with respect to its naturally occurring or engineered substrate.

The incubation according to step e) can be carried out in a reaction medium, preferably an aqueous medium, comprising the mixture obtained according to step d) of the method of the present invention and optionally water; a buffer such as a phosphate buffer, a carbonate buffer, an acetate buffer, a borate buffer, a citrate buffer and a tris buffer, or combinations thereof; alcohol, such as methanol and ethanol; ester such as ethyl acetate; ketone such as acetone; amide such as acetamide; and the like.

Furthermore, the incubation according to step e) can be carried out in a reaction medium as defined above, wherein optionally a surfactant or an organic solvent can be added, if necessary. Any surfactant capable of accelerating the formation of a complex carbohydrate as defined according to the present invention as a possible product of the invention can be used as the surfactant. Examples include non-ionic surfactants such as polyoxyethylene

octadecylamine (e.g., Nymeen S-215, manufactured by Nippon Oil & Fats); cationic surfactants, such as cetyltrimethylammonium bromide and alkyltrimethylbenzylammoniumchloride (e.g., Cation F2-40E, manufactured by Nippon Oil & Fats); anionic surfactants such as lauroyl sarcosinate; tertiary amines such as alkyltrimethylamine (e.g.,  
5 Tertiary Amine FB, manufactured by Nippon Oil & Fats); and the like, which are used alone or as a mixture of two or more. The surfactant can be used generally in a concentration of 0.1 to 50 g/l. The organic solvent can include xylene, toluene, fatty acid alcohol, acetone, ethyl acetate, and the like, which can be used in a concentration of generally 0.1 to 50 ml/l.

The incubation according to step e) can be furthermore carried out in a reaction medium as  
10 defined above, preferably having a pH 3 to 10, pH 5 to 10, preferably pH 6 to 8.

The incubation according to step e) can be furthermore carried out at a temperature of about 0 °C to about 100 °C, preferably at a temperature of about 10 to about 50 °C, e.g. at a temperature of about 20 °C to about 50 °C. When using enzymes from thermophilic organisms (e.g. *Thermotoga* sp.), even higher temperatures are beneficial, such as about 50 to  
15 about 80 °C, preferably at about 60 °C. In the reaction medium, inorganic salts, such as MnCl<sub>2</sub> and MgCl<sub>2</sub>, can be added, if necessary.

The incubation according to step e) of the method of the present invention can be carried out in a bioreactor. The bioreactor is preferably suitable for either a continuous mode or a discontinuous mode.

20 The incubation according to step e) can be carried out in a continuous or discontinuous mode. If carried out in a continuous mode, the method preferably provides for a continuous flow of compounds and/or enzymes as necessary, preferably by continuously providing educts of the reaction to the reaction mixture and continuously removing products from the reaction mixture, while maintaining the concentration of all components, including enzymes at a  
25 predetermined level. The enzymes used in a continuous mode can be added either in free form or as bound or immobilized to a surface.

With regard to certain embodiments of the method of the first aspect of the invention, the addition of donors and/or enzymes can be repeated according to an optional step f).

Particularly preferably, steps a), c), d) and e) can be repeated, preferably with the mixture

obtained according to step e). When repeating at least one of the steps a), c), d) and e), the at least one compound provided according to step a) is preferably different from that/those provided in the previous cycle, and the at least one enzyme provided according to step c) is preferably different from that/those provided in the previous cycle. Such a stepwise

5 proceeding can allow within multiple rounds the rational generation of a defined set of compounds in a controllable manner. It can also provide for a rational exclusion of specific components. To obtain such a variety of compounds, the compounds and/or enzymes can be added simultaneously or sequentially, and preferably compounds and/or enzymes can be added simultaneously in one step and/or sequentially in different steps.

10 Alternatively, a mixture with at least one compound as defined herein for step a) and mixture of oligosaccharides originated from a mammalian animal milk, preferably BMO, as defined herein for step b) and at least one enzyme as defined herein according to step c) can be incubated in one step without repetition of one or more steps. Such a proceeding can be preferable in certain circumstances, as it can lead to the largest variety of possible products.

15 The method of the first aspect of the invention preferably produces compounds on the basis of donors as provided in step a) and acceptors as provided in step b) upon adding enzymes according to step c) and incubating the mixture (step e)). An optional repetition of these steps can be carried out as described above. In this regard, according to the second aspect of the invention, the method as described above results in a mixture of modified (glycosylated)  
20 oligosaccharides.

In a preferred embodiment of the compounds of the second aspect, the modified (glycosylated) oligosaccharides are modified mammalian animal milk oligosaccharides, preferably modified cow, goat, sheep, water buffalo or yak milk oligosaccharides, more preferably modified cow milk oligosaccharides.

25 Also in a preferred embodiment of the compounds, the at least one glycosyl residue, which is different from galactosyl, comprised by the modified mammalian animal milk oligosaccharides can be linked to any of the monosaccharide units of the precursor mammalian animal milk oligosaccharides, preferably to a terminal galactosyl unit of the mammalian animal milk oligosaccharides. More preferably, said at least one glycosyl moiety  
30 can be a monosaccharide unit such as sialyl, fucosyl and/or N-acetylglucosaminy, or a

disaccharide unit such as N-acetyllactosaminyl, lacto-N-biosyl or sialylated and/or fucosylated N-acetylglucosaminyl, or tri-, tetra- or polysaccharide unit such as N-acetyllactosaminyl and lacto-N-biosyl moieties further glycosylated with sialyl and/or fucosyl and/or N-acetyllactosaminyl and/or lacto-N-biosyl and/or N-acetylglucosaminyl.

5 It is particularly preferred that compounds of the second aspect of the invention feature linkages and modifications characteristic of the method of the first aspect of the invention, used to make them. In this regard, the compounds obtained after incubation step e) and/or a repetition of steps according to step f) of the method are characterized in that one or more of the following are present:

- 10 - a N-acetyl-glucosaminyl group is attached to a galactosyl moiety of the mammalian animal milk oligosaccharide chain, preferably to a terminal galactosyl moiety of the mammalian animal milk oligosaccharide chain with 1-3, 1-4 or 1-6 interglycosidic linkage, preferably with 1-3 or 1-6 linkage,
- a N-acetyl-glucosaminyl group is attached to the galactosyl moiety of a N-acetyl-  
15 lactosaminyl or lacto-N-biosyl group with 1-3 or 1-6 interglycosidic linkage,
- a N-acetyl-lactosaminyl group is attached to the galactosyl moiety of another N-acetyl-lactosaminyl group with 1-3 or 1-6 interglycosidic linkage,
- a N-acetyl-lactosaminyl group is attached to the galactosyl moiety of a lacto-N-biosyl group with 1-3 or 1-6 interglycosidic linkage,
- 20 - a N-acetyl-lactosaminyl group is attached to a galactosyl moiety of the mammalian animal milk oligosaccharide chain, preferably to a terminal galactosyl moiety of the mammalian animal milk oligosaccharide chain with 1-3, 1-4 or 1-6 interglycosidic linkage, preferably with 1-3 or 1-6 linkage,
- a lacto-N-biosyl group is attached to the galactosyl moiety of a N-acetyl-lactosaminyl  
25 group with 1-3 or 1-6 interglycosidic linkage, preferably with 1-3 linkage,
- a lacto-N-biosyl group is attached to the galactosyl moiety of another lacto-N-biosyl group with 1-3 or 1-6 interglycosidic linkage, preferably with 1-3 linkage,

- a lacto-N-biosyl group is attached to a galactosyl moiety of the mammalian animal milk oligosaccharide chain, preferably to a terminal galactosyl moiety of the mammalian animal milk oligosaccharide chain with 1-3, 1-4 or 1-6 interglycosidic linkage, preferably with 1-3 or 1-6 linkage,
- 5    - a fucosyl residue attached to a N-acetyl-lactosaminyl and/or a lacto-N-biosyl group is linked to
  - the galactose of the lacto-N-biosyl group with 1-2 interglycosidic linkage and/or
  - the N-acetyl-glucosamine of the lacto-N-biosyl group with 1-4 interglycosidic linkage and/or
  - 10    ▪ the N-acetyl-glucosamine of the N-acetyl-lactosaminyl group with 1-3 interglycosidic linkage,
- a fucosyl residue is attached to a galactosyl moiety of the mammalian animal milk oligosaccharide chain, with 1-2 or 1-3 interglycosidic linkage,
- a fucosyl residue is attached to the galactose or glucose of moiety at the reducing end of  
15    the mammalian animal milk oligosaccharide with 1-2 or 1-3 interglycosidic linkage,
- a fucosyl residue is attached to a N-acetylglucosaminyl moiety, preferably to a terminal N-acetylglucosaminyl moiety with 1-3 or 1-4 interglycosidic linkage,
- a sialyl residue attached to the N-acetyl-lactosaminyl and/or the lacto-N-biosyl group is linked to
- 20    ▪ the galactose of the lacto-N-biosyl group with 2-3 interglycosidic linkage and/or
- the N-acetyl-glucosamine of the lacto-N-biosyl group with 2-6 interglycosidic linkage and/or
- the galactose of the N-acetyl-lactosaminyl group with 2-6 interglycosidic linkage,
- a sialyl residue is attached to a galactosyl moiety of the mammalian animal milk  
25    oligosaccharide chain, preferably to a terminal galactosyl moiety of the mammalian animal milk oligosaccharide chain with 2-3 or 2-6 interglycosidic linkage,



- a sialyl residue is attached to a N-acetylglucosaminy moiety, preferably to a terminal N-acetylglucosaminy moiety with 2-3 or 2-6 interglycosidic linkage,
  - a N-acetylgalactosaminy moiety, preferably to a terminal N-acetylgalactosaminy moiety with 2-3 or 2-6 interglycosidic linkage,
- 5    - a sialyl moiety with 2-8 interglycosidic linkage.

According to a further preferred embodiment, the interglycosidic linkages in the compounds of the invention are  $\beta$ , with the exception of fucosyl and sialyl residues which are attached via  $\alpha$ -linkage.

According to a further embodiment of the second aspect, the present invention provides a  
 10    compound, preferably a mixture of compounds obtained or obtainable by the method of the present invention as described herein. In this context, such a mixture of compounds obtained or obtainable by the method of the present invention as described herein is preferably to be understood as a mixture of at least 2 to 10, 2 to 20, 2 to 100, 2 to 200, or even more different compounds as generally defined above. Such compounds can be preferably selected without  
 15    restriction from any of the compounds as defined above.

The present invention also provides or utilizes salts of herein defined compounds. Such salts can be preferably selected from salts of the compounds defined above, which contain at least one sialyl residue: an associated ion pair consisting of the negatively charged acid residue of sialylated mammalian animal milk oligosaccharide and one or more cations in any  
 20    stoichiometric proportion. Cations, as used in the present context, are atoms or molecules with positive charge. The cation can be inorganic or organic. Preferred inorganic cations are ammonium ion, alkali metal, alkali earth metal and transition metal ions, more preferably  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$ ,  $\text{Ba}^{2+}$ ,  $\text{Fe}^{2+}$ ,  $\text{Zn}^{2+}$ ,  $\text{Mn}^{2+}$  and  $\text{Cu}^{2+}$ , most preferably  $\text{K}^+$ ,  $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$ ,  $\text{Ba}^{2+}$ ,  $\text{Fe}^{2+}$  and  $\text{Zn}^{2+}$ . Basic organic compounds in positively charged form can be relevant organic  
 25    cations. Such preferred positively charged counterparts are diethyl amine, triethyl amine, diisopropyl ethyl amine, ethanolamine, diethanolamine, triethanolamine, imidazole, piperidine, piperazine, morpholine, benzyl amine, ethylene diamine, meglumin, pyrrolidine, choline, tris-(hydroxymethyl)-methyl amine, N-(2-hydroxyethyl)-pyrrolidine, N-(2-hydroxyethyl)-piperidine, N-(2-hydroxyethyl)-piperazine, N-(2-hydroxyethyl)-morpholine, L-

arginine, L-lysine, oligopeptides having L-arginine or L-lysine unit or oligopeptides having a free amino group on the *N*-terminal, etc., all in protonated form. Such salt formations can be used to modify characteristics of the complex molecule as a whole, such as stability, compatibility to excipients, solubility and the ability to form crystals.

- 5 According to the third aspect of the invention, a mixture of compounds obtained or obtainable by a method of this invention has bifidogenic activity, preferably enhanced bifidogenic activity compared to the precursor mammalian animal milk oligosaccharides. This mixture of compounds is therefore particularly effective in the improvement and maturation of the immune system of neonatal infants, and has preventive effect against secondary infections
- 10 following viral infections such as influenza. The use of this mixture of compounds as a prebiotic enhances the beneficial effects and efficiency of probiotics, such as *Lactobacillus* and *Bifidobacterium* species, in promoting the development of an early bifidogenic intestinal microbiota in infants, in reducing the risk of development or allergy and/or asthma in infants, and in preventing and treating pathogenic infections in such as diarrhoea in infants.
- 15 According to the fourth aspect, the present invention provides a mixture of compounds obtained or obtainable by a method of this invention for use in enhancing the bifidogenic effect of consumable products. This mixture of compounds is particularly effective in the improvement and maturation of the immune system of neonatal infants, and has preventive effect against secondary infections following viral infections such as influenza. The use of
- 20 this mixture of compounds as a prebiotic enhances the beneficial effects and efficiency of probiotics, such as *Lactobacillus* and *Bifidobacterium* species, in promoting the development of an early bifidogenic intestinal microbiota in infants, in reducing the risk of development or allergy and/or asthma in infants, and in preventing and treating pathogenic infections such as diarrhoea in infants.
- 25 According to the fifth aspect of the invention, a mixture of compounds obtained or obtainable by a method of this invention can also be used for the preparation of a consumable product, preferably for the preparation of a pharmaceutical composition, a nutritional formulation or a food supplement. This mixture of compounds obtained or obtainable by the method of the invention is particularly effective in the improvement and maturation of the immune system
- 30 of neonatal infants, and has preventive effect against secondary infections following viral

infections such as influenza. The use of this compounds or mixture of compounds as a prebiotic enhances the beneficial effects and efficiency of probiotics, such as *Lactobacillus* and *Bifidobacterium* species, in promoting the development of an early bifidogenic intestinal microbiota in infants, in reducing the risk of development or allergy and/or asthma in infants, and in preventing and treating pathogenic infections such as diarrhoea in infants.

Preferred embodiments of the fifth aspect include pharmaceutical compositions, comprising a mixture of compounds obtained or obtainable by the method of the first aspect of the invention, and preferably a pharmaceutically acceptable carrier. "Pharmaceutically acceptable carriers" include additives, adjuvants, excipients and diluents (water, gelatine, talc, sugars, starch, gum arabic, vegetable gums, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, lubricants, colorants, fillers, wetting agents, etc.). Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field. The dosage form for administration includes, for example, tablets, powders, granules, pills, suspensions, emulsions, infusions, capsules, injections, liquids, elixirs, extracts and tinctures.

Preferred embodiments of the fifth aspect also include nutritional formulations such as foods or drinks, comprising a mixture of compounds obtained or obtainable by the method of the first aspect of the invention. The nutritional formulation can also contain edible micronutrients, vitamins and minerals as well. The amounts of such ingredient can vary depending on whether the formulation is intended for use with normal, healthy infants, children, adults or subjects having specialized needs (e.g. suffering from metabolic disorders). Micronutrients include, for example, edible oils, fats or fatty acids (such as coconut oil, soy-bean oil, monoglycerides, diglycerides, palm olein, sunflower oil, fish oil, linoleic acid, linolenic acid etc.), carbohydrates (such as glucose, fructose, sucrose, maltodextrin, starch, hydrolysed cornstarch, etc.) and proteins from casein, soy-bean, whey or skim milk, or hydrolysates of these proteins, but protein from other sources (either intact or hydrolysed) can be used. Vitamins can be chosen from the group consisting of vitamin A, B1, B2, B5, B6, B12, C, D, E, H, K, folic acid, inositol and nicotinic acid. The nutritional formula can contain the following minerals and trace elements: Ca, P, K, Na, Cl, Mg, Mn, Fe, Cu, Zn, Se, Cr or I.

According to a general embodiment of the fifth aspect, a nutritional formulation as defined above can further contain one or more probiotics, e.g. lacto bacteriae, *Bifidobacterium* species, prebiotics such as fructooligosaccharides and galactooligosaccharides, proteins from casein, soy-bean, whey or skim milk, carbohydrates such as lactose, saccharose, maltodextrin, starch or mixtures thereof, lipids (e.g. palm olein, sunflower oil, safflower oil) and vitamins and minerals essential in a daily diet. Probiotics are preferably also contained in the nutritional formulation in an amount sufficient to achieve the desired effect in an individual, preferably in infants, children and/or adults.

Preferably, such a nutritional formulation is an infant formula. The term “infant formula” preferably means a foodstuff intended for particular nutritional use by infants during the first 4-6 months or even 4 to 12 months of life and satisfying by itself the nutritional requirements of infants. It can contain one or more probiotic *Bifidobacterium* species, prebiotics such as fructooligosaccharides and galactooligosaccharides, proteins from casein, soy-bean, whey or skim milk, carbohydrates such as lactose, saccharose, maltodextrin, starch or mixtures thereof, lipids (e.g. palm olein, sunflower oil, safflower oil) and vitamins and minerals essential in a daily diet.

Such a nutritional formulation can also be a food supplement and can contain the same ingredients as set forth above for other nutritional formulations, such as vitamins, minerals, trace elements and other micronutrients. The food supplement can be for example in the form of tablets, capsules, pastilles or a liquid. The supplement can contain conventional additives selected from but not limited to binders, coatings, emulsifiers, solubilising agents, encapsulating agents, film forming agents, adsorbents, carriers, fillers, dispersing agents, wetting agents, gellifying agents, gel forming agents, etc.

According to a preferred embodiment, the food supplement is a digestive health functional food, as the administration of compounds or a mixture of compounds obtained or obtainable by the method of the present invention as described herein provides a beneficial effect on digestive health. A digestive health functional food is preferably a processed food used with the intention of enhancing and preserving digestive health by utilizing a mixture of compounds obtained or obtainable by the method of the present invention as described herein, as physiologically functional ingredients or components in the form of a tablet, capsule,

powder, etc. Different terms such as dietary supplement, nutraceutical, designed food, or health product can also be used to refer to a digestive health functional food.

In another preferred embodiment of the fifth aspect, a mixture of compounds obtained or obtainable by a method of this invention, can be used for the preparation of nutritional

5 formulations including foods, drinks and feeds, preferably infant formulae, food supplements and digestive health functional foods, preferably any of these as described above. The nutritional formulation can be prepared in any usual manner.

In still another preferred embodiment of the fifth aspect, a mixture of compounds obtained or obtainable by a method of the invention can be used for the preparation of nutritional

10 formulations including foods, drinks and feeds, preferably infant formulae, food supplements and digestive health functional foods, preferably any of these as described above. The nutritional formulation can be prepared in any usual manner.

According to the sixth aspect, the present invention provides a method for enhancing the bifidogenic effect of oligosaccharide compounds originating from a mammalian animal milk, the method comprising reacting at least one glycosyl donor with a mixture of oligosaccharides originating from a mammalian animal milk under the catalysis of an enzyme capable of transferring said glycosyl moiety, wherein the glycosyl moiety is not galactosyl.

15 According to a preferred embodiment of the sixth aspect, the method comprises the steps of:


- a) providing at least one glycosyl donor which is not a galactosyl donor,
- 20 b) providing oligosaccharides originating from a mammalian animal milk,
- c) providing at least one enzyme comprising a trans-glycosidase and/or a glycosynthase activity;
- d) preparing a mixture of the components provided in steps a), b) and c);
- e) incubating the mixture prepared according to step d);
- 25 f) optionally: repeating steps a), c), d) and e) with the mixture obtained according to step e).

This method can be suitably carried out in the same way as the method of the first aspect of the invention as described above.


Accordingly, the at least one glycosyl donor is preferably selected from the group consisting of a sialyl donor, a fucosyl donor, and an optionally galactosylated N-acetyl-glucosaminyl donor.

Preferably, in this method for enhancing the bifidogenic effect of oligosaccharide compounds originating from a mammalian animal milk the sialyl and/or fucosyl and/or optionally galactosylated N-acetyl-glucosaminyl donor has the leaving group selected from fluoro, azido and -OR group, wherein R can be a mono-, di- or oligosaccharide, glycolipid, glycoprotein or glycopeptide, cyclic or acyclic aliphatic group, or aryl residue, or the optionally galactosylated N-acetyl-glucosaminyl donor is an oxazoline.

Also preferably, the sialyl donor is characterized by formula 1, and/or the fucosyl donor is characterized by formula 2, and/or the optionally galactosylated N-acetyl-glucosaminyl donor is characterized by formulae 3 or 4



wherein X, independently, is selected from the group consisting of azide, fluoro, optionally substituted phenoxy, optionally substituted pyridinyloxy, lactose moiety, group A, group B, group C and group D




wherein  $R_a$  is independently H or alkyl, or two vicinal  $R_a$  groups represent a  $=C(R_b)_2$  group, wherein  $R_b$  is independently H or alkyl,  $R_c$  is independently selected from the

group consisting of alkoxy, amino, alkylamino and dialkylamino,  $R_d$  is selected from the group consisting of H, alkyl and  $-C(=O)R_e$ , wherein  $R_e$  is OH, alkoxy, amino, alkylamino, dialkylamino, hydrazino, alkylhydrazino, dialkylhydrazino or trialkylhydrazino;

- 5 and  $R_1$  and  $R_2$ , independently, is H or  $\beta$ -D-galactopyranosyl group with the proviso that at least one of the  $R_1$  and  $R_2$  groups is H.

More preferably, X in donors of formulae **1**, **2** or **3**, independently, is selected from a group consisting of 4-nitrophenoxy, 2-nitrophenoxy, 2,4-dinitrophenoxy, 2-chloro-4-nitrophenoxy, lactose moiety, 2,5-dimethyl-3-oxo-(2H)-furan-4-yloxy, 2-ethyl-5-methyl-3-oxo-(2H)-furan-4-yloxy, 5-ethyl-2-methyl-3-oxo-(2H)-furan-4-yloxy, 4,6-dimethoxy-1,3,5-triazin-2-yloxy, 4,6-diethoxy-1,3,5-triazin-2-yloxy, or 4-methylumbelliferyloxy, or the donor of formula **5** is selected from compounds of formulae **5**, **6** or **7**.



- According to the most preferred embodiments the donor of formula **1** is 3'-SL, 6'-SL or 2'-FL. In this method for enhancing the bifidogenic effect of oligosaccharide compounds originating from a mammalian animal milk, the mammalian animal is an ungulate and/or ruminant, preferably a domesticated ungulate and/or ruminant, more preferably cow, goat, sheep, water buffalo and yak, most preferably cow.

- In the present invention, if not otherwise indicated, different features of alternatives and embodiments can be combined with each other, where suitable.

Whilst the invention has been described with reference to a preferred embodiment, it will be appreciated that various modifications are possible within the scope of the invention.

- In this description of the invention, unless expressly otherwise indicated, the word 'or' is used in the sense of an operator that returns a true value when either or both of the stated conditions is met, as opposed to the operator 'exclusive or' which requires that only one of the conditions is met. The word 'comprising' is used in the sense of 'including' rather than to

mean 'consisting of'. All prior teachings acknowledged above are hereby incorporated by reference. No acknowledgement of any prior published document herein should be taken to be an admission or representation that the teaching thereof was common general knowledge in Australia or elsewhere at the date hereof.

## 5 EXPERIMENTAL

### Example 1

General procedure for transglycosylation reactions:

A solution of appropriate glycosyl donor(s) such as derivatives of general formula **1** to **4** and animal milk oligosaccharide mixture (10 mM –1M) is incubated in an incubation buffer at a  
10 pH range from 5.0 to 9.0 with recombinant glycosidase,  $\alpha$ -transglycosidase or  $\alpha$ -glycosynthase, such as  $\alpha$ -fucosidase,  $\alpha$ -transfucosidase,  $\alpha$ -fucosynthase,  $\alpha$ -sialidase,  $\alpha$ -transsialidase,  $\beta$ -N-acetylglucosaminidase,  $\beta$ -trans-N-acetylglucosaminidase,  $\beta$ -lacto-N-biosidase,  $\beta$ -trans-lacto-N-biosidase,  $\beta$ -N-acetyllactosaminidase or  $\beta$ -trans-N-acetyllactosaminidase. The reaction mixture is stirred at a temperature in the range of from 20  
15 to 70 °C. Samples are taken at different times of the reaction, the reaction is stopped by the addition of 1M NaHCO<sub>3</sub>-solution at pH=10 and products are analysed by HPLC, or/and LC-MS, or/and LC-MS-MS. After completion, the enzyme is denatured and centrifuged. The resulting solution is evaporated under reduced pressure. After lyophilisation, the dry residue is dissolved in water and products are purified by biogel chromatography (P-2 Biogel, 16x900  
20 mm) with water or by reverse phase chromatography.

The recombinant transglycosidases used in the examples 3 to 5 were produced in *E. coli* as reported by Osanjo et al. *Biochemistry* **46**, 1022 (2007), Agustí et al. *Glycobiology* **14**, 659 (2004), Neubacher et al. *Org. Biomol. Chem.* **3**, 1551 (2005) and Sun et al. *Biotechnol. Lett.* **30**, 671 (2008). The purified enzymes were stored between -20 and +4 °C.

25 BMOs used in examples 3 to 5: demineralized and delactosed bovine milk whey powder (WO 2012/161080) was membrane-filtered to remove proteins and freeze-dried.



## Example 2

### Manufacture of 2,5-dimethyl-3-oxo-(2H)-furan-4-yl $\alpha$ -L-fucopyranoside

- a) The solution of 2,3,4-tri-O-(4-methoxybenzyl)-L-fucopyranose trichloroacetimidate ( $\alpha/\beta$  mixture, prepared from 85 mmol of 2,3,4-tri-O-(4-methoxybenzyl)-L-fucopyranose and trichloroacetonitrile in the presence of NaH in quantitative yield) in diethyl ether (100 ml) was added to a mixture of 2,5-dimethyl-4-hydroxy-3-oxo-(2H)-furan (85 mmol) and TMS-triflate (1.2 ml) in diethyl ether (200 ml) at -14 °C. After 3 hours the cooling bath was removed and the stirring continued for 1 hour. The reaction mixture was diluted with ethyl acetate and extracted with sat. NaHCO<sub>3</sub>-solution (3 x 150 ml) and brine (150 ml). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The resulting syrup was purified by column chromatography yielding 23.27 g of 2,5-dimethyl-3-oxo-(2H)-furan-4-yl 2,3,4-tri-O-(4-methoxybenzyl)- $\alpha$ -L-fucopyranoside as a thick yellow syrup in a 1:1 mixture of diastereoisomers. Selected NMR chemical shifts in CDCl<sub>3</sub>: anomeric protons: 5.32 and 5.57 ppm,  $J_{1,2}$  = 3.4 Hz; anomeric carbons: 113.81 and 113.95 Hz.
- b) A suspension of the above product and Pd on charcoal (12.5 g) in ethyl acetate (1 l) was stirred at room temperature for 6 hours under H<sub>2</sub>. The catalyst was filtered off and washed with ethyl acetate. The combined filtrate was evaporated to a solid mass which was suspended in ethyl acetate and allowed to stand at 5 °C for overnight. The crystalline material was filtered off and dried. The mother liquor was subjected to column chromatography. The combined products gave 5.50 g of 2,5-dimethyl-3-oxo-(2H)-furan-4-yl  $\alpha$ -L-fucopyranoside as white solid in 1:1 mixture of diastereoisomers. Selected NMR chemical shifts in DMSO-d<sub>6</sub>: anomeric protons: 5.07 and 5.52 ppm,  $J_{1,2}$  = 2.6 Hz; anomeric carbons: 100.19 and 101.03 Hz. Purity by GC (after silylation): 98.9 %.

## Example 3

### Fucosylation of BMOs with 2'-FL as donor

A solution of 2'-FL (9.8 mg) and BMO (11.2 mg) and was incubated in the presence of  $\alpha$ -1,2-transfucosidase mutant P25 from *Thermotoga maritima* (Osanjo et al. *Biochemistry* **46**, 1022

(2007), 94 µg) according to the general procedure in an incubation buffer (50 mM citrate-phosphate, 145 mM NaCl, pH 5.5, 190 µl) at 60 °C for 24 hours.

Qualitative LC-MS analysis was carried out to analyse the composition of the modified BMO mixture based on the method described by Hernández-Hernández et al. *J. Chromatogr. A* **1220**, 57 (2012).

Experimental conditions:

Instrument: Bruker microQTof II MS coupled with Dionex Ultimate 3000 UHPLC

Ionisation: ESI negative

Dry temperature: 200 °C

Calibration: with Na-formate cluster solution

Applied HPLC method:

Column	XBridge™ Amide 3.5µm, 4.6x250mm		
Temperature oven (°C)	35		
Flow (ml/min)	1.0, split to MS 1:1		
Mobile phase	A: water with 0.1 % ammonium hydroxide B: acetonitrile with 0.1 % ammonium hydroxide		
Elution type:	gradient		
Gradient profile:	time [min]	A [%]	B [%]
	0	20	80
	35	50	50
	40	50	50
	40.5	20	80
	45	20	80
Test time (min):	45		
Autosampler temperature (°C):	10		
Injected volume (µl)	5		

New fucosylated oligosaccharides detected:

BMOs after fucosylation (ret. time, min)	
Fuc-Hex <sub>2</sub> [M-H] <sup>-</sup> 487	16.80
	17.03

	17.33 (2'-FL)
	17.55
Fuc-Hex <sub>3</sub> [M-H] <sup>-</sup> = 649	21.31
	21.73
	22.03
	22.38
	22.80
Fuc-HexNAc-Hex <sub>2</sub> [M-H] <sup>-</sup> = 690	13.98
	14.65
	15.32

(Hex: hexose moiety; HexNAc: N-acetyl-deoxyaminohexose moiety; Fuc: fucosyl moiety)

#### Example 4

Sialylation of BMOs with 3'-SL as donor

- 5 A solution of 3'-SL (2.6 mg) and BMO (50.6 mg) and was incubated in the presence of  $\alpha$ -2,3-transsialidase from *T. cruzi* (GenBank Database gi|432485, 1  $\mu$ g) according to the general procedure in an incubation buffer (100 mM tri-HCl, pH 7.5, 180  $\mu$ l) at 37 °C for 24 hours. Qualitative LC-MS analysis was carried out to identify new sialylated galactooligosaccharides (see Example 3 for conditions).
- 10 Result of the HPLC analysis:

BMOs before sialylation (ret. time, min)		BMOs after sialylation (ret. time, min)	
Hex <sub>2</sub> [M-H] <sup>-</sup> = 341	15.10	Hex <sub>2</sub> [M-H] <sup>-</sup> = 341	15.04
	16.14		15.94
	17.17		16.53
	18.76		17.00
	20.35		18.54
			20.20
Hex <sub>3</sub> [M-H] <sup>-</sup> = 503	20.35	Hex <sub>3</sub> [M-H] <sup>-</sup> = 503	20.20
	21.04		20.85
HexNAc-Hex <sub>2</sub> [M-H] <sup>-</sup> = 544	18.25	HexNAc-Hex <sub>2</sub> [M-H] <sup>-</sup> = 544	18.12

Neu5Ac-Hex <sub>2</sub> [M-H] <sup>-</sup> = 632	4.93	Neu5Ac-Hex <sub>2</sub> [M-H] <sup>-</sup> = 632	4.98
	5.25 (3'-SL)		5.37 (3'-SL)
	5.72 (6'-SL)		5.80
	6.47		6.20
	6.84		6.72
		Neu5Ac-Hex <sub>3</sub> [M-H] <sup>-</sup> = 794	7.51
			7.78
			8.05
			8.47
			8.87

(Hex: hexose moiety; HexNAc: N-acetyl-deoxyaminohexose moiety; Neu5Ac: sialyl moiety)

#### Example 5

Sialylation of GOS with 6'-SL as donor

A solution of 6'-SL (2.6 mg) and BMO (25.3 mg) and was incubated in the presence of  
 5 recombinant truncated  $\alpha$ -2,6-transsialidase  $\Delta$ 15Pd2,6ST from *Photobacterium damsela*  
 (Cheng et al. *Glycobiology* **20**, 260 (2010), 60  $\mu$ g) according to the general procedure in an  
 incubation buffer (100 mM phosphate buffer, pH 6.0, 190  $\mu$ l) at 37 °C for 24 hours.

Qualitative LC-MS analysis was carried out to identify new sialylated galactooligosaccharides  
 (see Example 3 for conditions).

10 Result of the HPLC analysis:

BMOs before sialylation (ret. time, min)		BMOs after sialylation (ret. time, min)	
Hex <sub>2</sub> [M-H] <sup>-</sup> = 341	15.10	Hex <sub>2</sub> [M-H] <sup>-</sup> = 341	14.95
	16.14		15.93
	17.17		16.55
	18.76		17.01
	20.35		18.52
			20.17
Hex <sub>3</sub> [M-H] <sup>-</sup> = 503	20.35	Hex <sub>3</sub> [M-H] <sup>-</sup> = 503	20.18
	21.04		20.82


HexNAc-Hex <sub>2</sub> [M-H] <sup>-</sup> = 544	18.25	HexNAc-Hex <sub>2</sub> [M-H] <sup>-</sup> = 544	18.12
Neu5Ac-Hex <sub>2</sub> [M-H] <sup>-</sup> = 632	4.93	Neu5Ac-Hex <sub>2</sub> [M-H] <sup>-</sup> = 632	4.39
	5.25 (3'-SL)		4.88
	5.72 (6'-SL)		5.27
	6.47		6.42 (6'-SL)
	6.84		7.63
			8.15
		Neu5Ac-Hex <sub>3</sub> [M-H] <sup>-</sup> = 794	7.80
			8.87
			9.05
			9.47
			9.92
		Neu5Ac-HexNAc-Hex <sub>2</sub> [M-H] <sup>-</sup> = 835	7.65

(Hex: hexose moiety; HexNAc: N-acetyl-deoxyaminohexose moiety; Neu5Ac: sialyl moiety)


## CLAIMS

1. A method for making a mixture of oligosaccharides originating from a mammalian animal milk, comprising:
  - 5 - reacting at least one glycosyl donor with a mixture of oligosaccharides originating from a mammalian animal milk under the catalysis of an enzyme capable of transferring said glycosyl moiety, wherein the glycosyl donor is not a galactosyl donor.
2. The method according to claim 1, the method comprising the steps of
  - 10 a) providing at least one glycosyl donor,
  - b) providing a mixture of oligosaccharides originating from a mammalian animal milk,
  - c) providing at least one enzyme comprising a trans-glycosidase and/or a glycosynthase activity;
  - 15 d) preparing a mixture of the components provided in steps a), b) and c);
  - e) incubating the mixture prepared according to step d);
  - f) optionally: repeating steps a), c), d) and e) with the mixture obtained according to step e).
3. The method according to claim 1 or claim 2, wherein the at least one glycosyl donor is
  - 20 selected from the group consisting of a sialyl donor, a fucosyl donor, and an optionally galactosylated N-acetyl-glucosaminyl donor.
4. The method according to any one of claims 1 to 3, wherein the sialyl and/or fucosyl and/or optionally galactosylated N-acetyl-glucosaminyl donor has the leaving group selected from fluoro, azido and -OR group, wherein R can be a mono-, di- or
  - 25 oligosaccharide, glycolipid, glycoprotein or glycopeptide, cyclic or acyclic aliphatic group, or aryl residue, or the optionally galactosylated N-acetyl-glucosaminyl donor is an oxazoline.

5. The method according to claim 4, wherein the sialyl donor is characterized by formula **1**, and/or the fucosyl donor is characterized by formula **2**, and/or the optionally galactosylated N-acetyl-glucosaminyl donor is characterized by formulae **3** or **4**



- 5 wherein X, independently, is selected from the group consisting of azide, fluoro, optionally substituted phenoxy, optionally substituted pyridinyloxy, lactose moiety, group **A**, group **B**, group **C** and group **D**




- 10 wherein  $R_a$  is independently H or alkyl, or two vicinal  $R_a$  groups represent a  $=C(R_b)_2$  group, wherein  $R_b$  is independently H or alkyl,  $R_c$  is independently selected from the group consisting of alkoxy, amino, alkylamino and dialkylamino,  $R_d$  is selected from the group consisting of H, alkyl and  $-C(=O)R_e$ , wherein  $R_e$  is OH, alkoxy, amino, alkylamino, dialkylamino, hydrazino, alkylhydrazino, dialkylhydrazino or trialkylhydrazino;

- 15 and  $R_1$  and  $R_2$ , independently, is H or  $\beta$ -D-galactopyranosyl group with the proviso that at least one of the  $R_1$  and  $R_2$  groups is H.

6. The method according to claim 5, wherein X in donors of formulae **1**, **2** or **3**, independently, is selected from a group consisting of 4-nitrophenoxy, 2-nitrophenoxy, 2,4-dinitrophenoxy, 2-chloro-4-nitrophenoxy, lactose moiety, 2,5-dimethyl-3-oxo-

(2H)-furan-4-yloxy, 2-ethyl-5-methyl-3-oxo-(2H)-furan-4-yloxy, 5-ethyl-2-methyl-3-oxo-(2H)-furan-4-yloxy, 4,6-dimethoxy-1,3,5-triazin-2-yloxy, 4,6-diethoxy-1,3,5-triazin-2-yloxy, or 4-methylumbelliferyloxy, or the donor of formula **5** is selected from compounds of formulae **5**, **6** or **7**.



7. The method according to claim 6, wherein the donor of formula **1** is 3'-SL or 6'-SL.
8. The method according to claim 6, wherein the donor of formula **2** is 2'-FL.
9. The method according to any one of claims 1 to 8, wherein the mammalian animal is an ungulate and/or ruminant, preferably a domesticated ungulate and/or ruminant, more preferably cow, goat, sheep, water buffalo and yak, most preferably cow.
10. The method according to any one of claims 1 to 9, for enhancing the bifidogenic effect of oligosaccharide compounds originating from a mammalian animal milk.
11. A mixture of modified oligosaccharides obtainable by the method according to any one of claims 1 to 9.
12. The use of the mixture of compounds according to claim 11 for enhancing the bifidogenic effect of a consumable product.
13. A consumable product, preferably a nutritional formulation, a pharmaceutical formulation or a food supplement, comprising a mixture of modified oligosaccharides according to claim 11 and nutritionally and/or pharmaceutically acceptable carriers, preferably for enhancing bifidogenic effect.
14. The consumable product according to claim 13, further comprising a further prebiotic and/or a probiotic.
15. The consumable product according to claim 13 or claim 14, which is an infant, follow-up or toddler formula, preferably an infant formula.



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2013/055179

## A. CLASSIFICATION OF SUBJECT MATTER

According to International Patent Classification (IPC)

C07H 1/00, C07H 3/06, C07H 5/06, C12P 19/18, C12P 19/26, C12P 19/44 (all version 2006.01)

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07H C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

DK, NO, SE, FI: Classes as above.

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPODOC, WPI, FULL TEXT: ENGLISH, HCAPLUS, FROSTI, AGRICOLA, BIOSIS, FSTA.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LEE, S.-G. et al.: "Production of sialyloligosaccharides by <i>trans</i> -sialidase catalyzed reaction using fetuin as a sialic acid donor", ENZYME AND MICROBIAL TECHNOLOGY, Vol. 31, pages 742-746 (2002). See entire document, in particular abstract; page 742, left column, lines 1-18; page 742, right column, lines 15-18 and Table 1.	1-14
X	VETERE, A. et al.: "Complete synthesis of 3'-sialyl-N-acetylglucosamine by regioselective transglycosylation", FEBS LETTERS, Vol. 399, pages 203-206 (1996). See entire document, in particular section 2.5, page 203; section 2.6, page 204 and Fig. 1, page 204.	1-14
X	WO 96/32492 A1 (CYTEL CORPORATION (US)) 17/10/1996. See page 2, lines 13-14; page 7, lines 8-13; examples and claims 1 and 15.	1-3, 7-14
X	ICHIKAWA, Y. et al.: "Enzyme-Catalyzed Oligosaccharide Synthesis", ANALYTICAL BIOCHEMISTRY, Vol. 202, pages 215-238 (1992). See entire document, in particular page 218, right column, lines 8-39; pages 219, left column, line 1-page 220, right column, line 2 and tables 4 and 5.	1-3, 7-14

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

17/11/2013

Date of mailing of the international search report

22/11/2013

Name and mailing address of the ISA

Nordic Patent Institute

Helgeshøj Allé 81

DK - 2630 Taastrup, Denmark.

Facsimile No. + 45 43 50 80 08

Authorized officer

Hans Christian Rudbeck

Telephone No. +45 43 50 81 25

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2013/055179

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93/24505 A1 (ALBERTA RESEARCH COUNCIL (CA)) 09/12/1993. See page 24, lines 14-17; page 189, line 5- page 190, line 24; page 190, line 27 – page 191, line 18 and figure 38.	1-3, 7-14
A	WO 2007/090894 A1 (NESTEC S.A. (CH)) 16/08/2007.	
A	WO 2009/144137 A1 (NESTEC S.A. (CH)) 03/12/2009.	
A	EP 2455387 A1 (NESTEC S.A. (CH)) 23/05/2012.	
A	US 5716812 A (WITHERS, S.G. et al.) 10/02/1998. See example 6.	
A	WO 98/46784 A1 (THE UNIVERSITY OF BRITISH COLOUMBIA (CA)) 22/10/1998.	
P,X	WO 2012/156897 A1 (GLYCOM A/S (DK)) 22/11/2012.	1-14
E, X	WO 2013/110778 A1 (ARLA FOODS AMBA (DK)) 01/08/2013.	

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
PCT/IB2013/055179

Patent document cited in search report / Publication date		Patent family member(s) / Publication date	
WO 9632492 A1	1996.10.17	CA 2218120 A1	1996.10.17
		CA 2218120 C	2008.09.16
		AU 5445396 A	1996.10.30
		EP 0820520 A1	1998.01.28
		EP 0820520 B1	2002.08.14
		US 5876980 A	1999.03.02
		JPH 11503328 A	1999.03.26
		US 5922577 A	1999.07.13
		US 6030815 A	2000.02.29
		AT 222294T T	2002.08.15
		DK 0820520T T3	2002.12.02
		ES 2180757T T3	2003.02.16
		DE 69623005T T2	2003.04.03
WO 9324505 A1	1993.12.09	WO 9222662 A1	1992.12.23
		CA 2110997 A1	1992.12.23
		WO 9222564 A1	1992.12.23
		WO 9222301 A1	1992.12.23
		CA 2110707 A1	1992.12.23
		CA 2110495 A1	1992.12.23
		CA 2118405 A1	1993.09.12
		WO 9324506 A1	1993.12.09
		CA 2118522 A1	1993.12.09
		EP 0588852 A1	1994.03.30
		EP 0591256 A1	1994.04.13
		EP 0591254 A1	1994.04.13
		JPH 06510661 A	1994.12.01
		JPH 06510746 A	1994.12.01
		US 5374655 A	1994.12.20
		JPH 07502011 A	1995.03.02
		EP 0643718 A1	1995.03.22
		EP 0643718 A4	1998.08.05
		EP 0650492 A1	1995.05.03
		JPH 07507319 A	1995.08.10
		JP 2823358B B2	1998.11.11
		JPH 07507312 A	1995.08.10
		US 5550155 A	1996.08.27
		US 5580858 A	1996.12.03
		US 5646123 A	1997.07.08

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.

PCT/IB2013/055179

Patent document cited in search report / Publication date		Patent family member(s) / Publication date	
WO 2007090894 A1	2007.08.16	CA 2641842 A1	2007.08.16
		AU 2007213677 A1	2007.08.16
		AU 2007213677B B2	2012.04.05
		EP 1988786 A1	2008.11.12
		EP 1988786 B1	2010.05.19
		CN 101400267 A	2009.04.01
		CN 101400267B B	2011.11.23
		US 2009092729 A1	2009.04.09
		US 8361530 B2	2013.01.29
		ZA 200807763 A	2009.11.25
		RU 2008136419 A	2010.03.20
		RU 2430631 C2	2011.10.10
		AT 468027T T	2010.06.15
		PT 1988786E E	2010.06.22
		ES 2342625T T3	2010.07.09
		BRPI 0707620 A2	2011.05.10
		MY 146109 A	2012.06.29
WO 2009144137 A1	2009.12.03	EP 2127661 A1	2009.12.02
		CA 2725051 A1	2009.12.03
		AU 2009253281 A1	2009.12.03
		EP 2143341 A1	2010.01.13
		WO 2010003803 A1	2010.01.14
		CA 2725039 A1	2010.01.14
		AU 2009268222 A1	2010.01.14
		TW 201002216 A	2010.01.16
		TW 201006392 A	2010.02.16
		MX 2010012905 A	2010.12.21
		MX 2011000284 A	2011.02.25
		US 2011064707 A1	2011.03.17
		EP 2303294 A1	2011.04.06
		EP 2309876 A1	2011.04.20
		US 2011110904 A1	2011.05.12
		CN 102065872 A	2011.05.18
		CN 102088871 A	2011.06.08
		CN 102088871B B	2013.01.02
		RU 2010153257 A	2012.07.10
		RU 2011104195 A	2012.08.20
EP 2455387 A1	2012.05.23	US 2013224331 A1	2013.08.29
		SG 192472 A1	2013.08.30
		CA 2818505 A1	2012.05.31
		WO 2012069415 A1	2012.05.31
		TW 201225852 A	2012.07.01

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.

PCT/IB2013/055179

Patent document cited in search report / Publication date		Patent family member(s) / Publication date	
		AU 2011333860 A1	2013.05.30
		SG 190262 A1	2013.06.28
		MX 2013005863 A	2013.07.05
		US 2013236423 A1	2013.09.12
		EP 2643336 A1	2013.10.02
US 5716812 A		1998.02.10	
		WO 9721822 A2	1997.06.19
		WO 9721822 A3	1997.08.28
		US 6284494 B1	2001.09.04
		US 2003100749 A1	2003.05.29
		US 7078194 B2	2006.07.18
WO 9846784 A1		1998.10.22	
		CA 2286456 A1	1998.10.22
		AU 7020498 A	1998.11.11
		US 5952203 A	1999.09.14
		EP 0973932 A1	2000.01.26
		US 6204029 B1	2001.03.20
		AU 739383B B2	2001.10.11
		JP 2001519669 A	2001.10.23
WO 2012156897 A1		2012.11.22	
		CA 2827294 A1	2012.08.30
		WO 2012113405 A1	2012.08.30
		WO 2012113404 A1	2012.08.30
		CA 2830025 A1	2012.09.27
		WO 2012127410 A1	2012.09.27
		WO 2012156898 A1	2012.11.22
		AU 2012232727 A1	2013.09.26
WO 2013110778 A1		2013.08.01	
		EP 2620506 A1	2013.07.31

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2013/055179

The glucosylation of the terminal galactosyl unit of an oligosaccharide under the catalysis of an enzyme is well-known to a person skilled in the art. The enhanced bifidogenic effect mentioned in claim 1 is an inherent effect of the glycosylation and therefore does not establish novelty over the general technical field. The documents cited in this report represent an arbitrary selection of the relevant documents.